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https://doi.org/10.1016/j.chembiol.2021.02.023SUMMARYTryptophan biosynthesis represents an important potential drug target for new anti-TB drugs. We identified a
series of indole-4-carboxamides with potent antitubercular activity. In vitro,Mycobacterium tuberculosis (Mtb)
acquired resistance to these compounds through three discretemechanisms: (1) a decrease in drugmetabolism
via loss-of-functionmutations in the amidase that hydrolyses these carboxamides, (2) an increased biosynthetic
rate of tryptophan precursors via loss of allosteric feedback inhibition of anthranilate synthase (TrpE), and (3)
mutationof tryptophansynthase (TrpAB) thatdecreased incorporationof4-aminoindole into4-aminotryptophan.
Thus, these indole-4-carboxamides act as prodrugs of a tryptophan antimetabolite, 4-aminoindole.INTRODUCTION
Mycobacterium tuberculosis (Mtb), the causative agent of tuber-
culosis (TB), continues to take its toll on humanity with about 7
million new infections and 1.5 million people succumbing to
the disease in 2018 (WHO, 2020). While the outlook looks dire
with the rise of strains resistant to one or more of the clinically
approved drugs for TB, several new compounds with novel tar-
gets have reached clinical trials (Libardo et al., 2018), and treat-
ment shortening regimens are being developed (Lee et al., 2020),
offering hope to patients. The rise of multidrug-resistant Mtb re-
flects a vast repertoire of mechanisms the bacillus deploys to
subvert drug action—from target modification to drug efflux
and degradation (Mabhula and Singh, 2019). A thorough under-
standing of a drug’s mechanism of action and the ways in which
Mtb resist their cidal effects is paramount to developing next-
generation antitubercular compounds.
Tryptophan biosynthesis represents a promising pathway to
target with novel drugs. Chorismate from the shikimate pathway
is converted to L-tryptophan (L-Trp) in six enzymatic steps
(Figure 1A). The first committed step in the biosynthesis is cata-
lyzed by anthranilate synthase (TrpE). Anthranilate is converted
to indole-3-glycerolphosphate by the actions of TrpD, TrpF, andCell Chemical Biology 28, 1–12,
This is an open access article undTrpC. The heterotetrameric tryptophan synthase (TrpAB) complex
catalyzes the last two steps; the a subunit splits indole-3-glycerol-
phosphate (IGP) to indole and glyceraldehyde-3-phosphate (G3P)
and the b subunit condenses indolewith L-serine (L-Ser) to formL-
Trp. Due to the high energetic cost associated with the biosyn-
thesis of L-Trp, this pathway is regulated both transcriptionally
(Merino et al., 2008) and allosterically by L-Trp (Calhoun et al.,
1973). Mtb that were made auxotrophic for L-Trp by deletion of
either trpE or trpA failed to persist in axenic culture and were avir-
ulent inmice (Wellington et al., 2017; Zhang et al., 2013), establish-
ing the essentiality of the pathway to the pathogenesis of Mtb. On
the host side, interferon-g-activatedmacrophages induce expres-
sionof indoleamine-2,3-dioxygenase-1 (IDO-1),which leads to the
conversion of L-Trp to kynerunine, a process that inhibits the
growth of intracellular pathogens with L-Trp auxotrophy (Ibana
et al., 2011). This strategy, however, is not effective against Mtb
and other bacteria capable of de novo L-Trp biosynthesis. Never-
theless, catabolism of L-Trp by IDO-1 was evident in plasma
samples obtained from patients with either active or latent TB
(Adu-Gyamfi et al., 2020; Collins et al., 2020), further implicating
the importance of L-Trp biosynthesis in Mtb infection. Indeed,
chemical inhibition of bacterial L-Trp biosynthesis was shown to
synergize with the host-induced L-Trp starvation to afford MtbAugust 19, 2021 ª 2021 The Authors. Published by Elsevier Ltd. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Antimycobacterial indole-4-carboxamides
(A) The tryptophan biosynthesis pathway and the enzymes (in red) catalyzing each transformation.
(B) Structures of the compounds used in this study.
(C) J774 macrophages were infected with Mtb H37Rv (multiplicity of infection = 1:10) and treated with the corresponding compound at the indicated concen-
trations for 7 days. Themacrophages were lysed and surviving Mtbwere enumerated by plating multiple dilutions in 7H11 plates. Limit of detection = 10 CFU/mL.
Bars represent mean ± SEM (n = 4). *p < 0.001 using one-way ANOVA.
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targeting this pathway for Mtb chemotherapy.
Several recent studies established the susceptibility to phar-
macological control of this essential mycobacterial pathway by
multiple scaffolds. First, an azetidine (BRD4592), a sulfolane,
and an indoline-5-sulfonamide all tightly bind to the interfacial re-
gion of TrpAB, stabilizing the closed, active state of the complex
and inhibiting both subunits of the enzyme (Abrahams et al.,
2017; Michalska et al., 2020; Wellington et al., 2017). Second,
indole propionic acid mimics L-Trp and inhibits TrpE by binding
to the allosteric L-Trp binding site (Negatu et al., 2019). Third,
benzoate-based compounds bind to the TrpD active site and
competitively inhibit the phosphoribosyl transferase activity
(Castell et al., 2013; Evans et al., 2014). Finally, fluoroanthrani-
lates, rather than inhibiting a discrete enzyme in the pathway,
are utilized as a substrate to form fluorotryptophans, which are
proposed to inhibit the growth of Mtb (Nurul Islam et al., 2019).
Here, we report a series of antimycobacterial indole-4-carbox-
amide prodrugs that liberate 4-aminoindole, which inhibits
neither TrpE nor TrpAB, but rather is metabolically incorporated
to form 4-aminotryptophan. We uncovered resistance mecha-
nisms that illustrate how modulation of metabolic flux effectively
rescues Mtb from the toxic incorporation of 4-aminoindole.
RESULTS
Mutants resistant to indole-4-carboxamides clustered
into two distinct groups
A series of small molecules consisting of carboxamidated indo-
leamine derivatives were obtained from an initial hit compound2 Cell Chemical Biology 28, 1–12, August 19, 2021identified from a high-throughput whole-cell screen for inhibitors
of Mtb growth. We studied the antimycobacterial properties and
the mechanism of action of representative members of the
series; compounds C1 through C4 (Figure 1B). All four com-
pounds were found to have potent activity, inhibiting growth of
both Mtb and M. bovis BCG at low mM concentrations in BSA-
free media (Tables 1 and S1). Furthermore, C1 was not toxic to
J774 macrophages (Figure S1) and afforded a 1.5 log reduction
in intracellular Mtb titer when tested in a murine macrophage
model of infection (Figure 1C).
To determine the mechanism of action, we isolated resistant
mutants of M. tuberculosis on solid medium containing C1 at
five times the in vitro MIC (minimum inhibitory concentration).
Spontaneous resistance was observed at frequencies that
varied depending on the number of bacilli plated; that is, when
107 CFU (colony-forming unit) was plated, the frequency of resis-
tance (FoR) was ~33 106, whereas at higher cell densities (109
CFU), the FoR was ~33 108. Determination of C1MICs against
these mutants revealed high-level (>12-fold) resistance from the
first group of mutants (5A-5I) and intermediate-level (4- to 8-fold)
resistance in the latter group (5J-5O) (Table 1). These mutants
were not only cross-resistant to C2, C3, and C4, but also
exhibited a level of resistance similar to that seen with C1,
indicating that the four compounds likely have identical
mechanisms. The congruence between FoR and MICs sug-
gested distinct mechanisms of resistance between the two
mutant groups.
Whole-genome sequencing revealed two genomic loci whose
single-nucleotide polymorphisms (SNPs) potentially conferred
resistance against C1 (Table 1). The mutants that appeared at




MutationC1 C2 C3 C4 4-AI C5 INH
WT 1.56 3.12 6.25 3.12 4.68 0.39 0.12 –
5A >100 75 >100 75 4.68 0.39 0.12 amiC K195*
5B >100 75 >100 75 4.68 0.39 0.12 amiC W238*
5G >100 75 >100 75 4.68 0.39 0.12 amiC S157F
5H >100 75 >100 75 4.68 0.39 0.12 amiC + g in aa352
5I >100 75 >100 75 4.68 0.39 0.12 amiC + g in aa352
5J 6.25 25 >100 25 100 0.39 0.12 trpB A168V
5K 6.25 25 >100 25 100 0.39 0.12 trpB A134V
5L 6.25 25 >100 25 100 0.39 0.12 trpE H170R
5M 6.25 25 >100 25 100 0.098 0.12 trpB D261G
5N 6.25 25 >100 25 100 0.19 0.12 trpA D54G
5O 6.25 25 >100 25 100 0.19 0.12 trpB D261G
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ated with mutations in a non-essential, putative amidase AmiC
(rv2888c). On the other hand, the low FoRmutants that appeared
with higher cell density had missense mutations in either
anthranilate synthase subunit I (TrpE, rv1609), or the a or b
subunit of tryptophan synthase (TrpA, rv1613; or TrpB, rv1612),
all of which are essential enzymes in the tryptophan biosynthetic
pathway (Wellington et al., 2017; Zhang et al., 2013).
AmiC mutations abolishes degradation of C1
The homolog of amiC inM. smegmatis (Msm) (msmeg_2521) was
shown to function as an inducer of acetamidase expression to
allow growth using amides as a sole carbon source (Roberts
et al., 2003). While Msm AmiC is only 65% identical to AmiC in
Mtb, one of the residues that was mutated (Ser157) in the
amiC mutants is highly conserved in several mycobacterial
species. The non-essential nature of amiC in Mtb coupled with
its putative function led us to speculate that it was involved in
C1 metabolism. Overexpression of AmiC, via introduction of an
extrachromosomal copy of rv2888c under the control of the
strong mycobacterial promoter (Psmyc) (Ehrt et al., 2005), did
not result in a noticeable change in MIC against C1 (Figure 2A),
suggesting that AmiC was not the direct target of C1.
We next incubated the compoundswith liveMtb andmonitored
the levels of the parent amides via liquid chromatography-mass
spectrometry (LC-MS). We observed complete disappearance
of the parent compoundpeak fromC1after 2 hwith a concomitant
appearance of a peak with an m/z corresponding to the free car-
boxylic acid (Figure 2B). The m/z of the free indoleamine was also
found, eluting in the void volume. The hydrolysis of C1 proceeding
to completionwithwild-type (WT) levels of AmiCalso explainswhy
overexpression of this protein did not decrease the MIC. In addi-
tion, the rate of degradation seemed to be correlated with MICs,
as C1 was completely metabolized within 2 h, whereas the less-
active derivative C3 showed residual levels of the amide after
24 h (Figure 2B). To establish drugmetabolism in the various resis-
tant strains we had isolated, we performed the same assay in
representative mutants. We found that the amiC mutants had
lost the ability to metabolize C1 while mutants in L-Trpbiosynthesis had no effect on metabolism (Figure 2C). This sug-
gested that the amiC mutations were loss-of-function mutations
that prevented hydrolysis of the amides. Whether AmiC directly
hydrolyses C1 or regulates the expression of other amidases—
like its homolog in Msm—was not explored in this study. We
note, however, that compounds C1 through C4 were all inactive
in M. smegmatis (Table S1).
The fact that amiC mutations resulting in abrogated amide
hydrolysis leads to high-level resistance also suggests that C1
is a pro-drug liberating an active metabolite from amide hydroly-
sis. We therefore determined whether the amine or the carbox-
ylic acid that would result from hydrolysis of C1were responsible
for the observed activity. All four representative compounds
share the 4-aminoindole (4-AI) moiety but differ in the carboxylic
acid coupling partner. Measuring the MIC of these building
blocks showed that only 4-AI was active against Mtb (MIC =
4.68 mM), while the free acids had little to no potency
(Table S2). In addition, members of this compound series in
which the carboxamide linkage is altered (either via N-methyl-
ation, replacement with a secondary amine linker, or flipped
such that the indole carries the carboxylic acid) were all inactive
against Mtb (compounds C10–C13 in Table S3), further support-
ing that 4-AI was responsible for the observed activity. Unsur-
prisingly, the amiC mutants were not cross-resistant to 4-AI (a
molecule that bypasses the AmiC hydrolysis requirement), while
the trpABEmutants were highly resistant to it (Table 1), indicating
that 4-AI derived from the AmiC-mediated hydrolysis of indole-4-
carboxamides likely targets L-Trp biosynthesis.
4-AI induce perturbations in tryptophan biosynthesis
Having established the role of AmiC in the activity of C1, we set
out to study the effect of C1 and 4-AI on tryptophan biosynthesis.
We first confirmed that the SNPs in the tryptophan biosynthetic
genes were resistance conferring by reintroducing a subset
of the mutations to a WT Mtb H37Rv background. We
electroporated Mtb with single-stranded oligonucleotides to
replace the native copies of trpB or trpE with the mutant alleles
by cellular recombineering (Murphy et al., 2015). We co-electro-
porated the cells with an oligo that would introduce the RpsLCell Chemical Biology 28, 1–12, August 19, 2021 3
Figure 2. Loss-of-function mutations in AmiC result in decreased
hydrolysis of indole-4-carboxamides
(A) AmiC was overexpressed in H37Rv by introducing an extrachromosomal
copy of rv2888c under the control of the Psmyc promoter (see STAR methods
for details). The MIC of the WT and the overexpressing strains were measured
using a standard broth microdilution method in BSA-free media. Results
shown are representative of three independent trials.
(B) To study Mtb-promoted compound metabolism, log phase Mtb cells
(OD600 = 3.0) were exposed to 103 MIC of C1 (left) or C3 (right) in PBS and
small aliquots were withdrawn, and quenched with acetonitrile and then in-
jected into the LC-MS. The chromatograms shown are representative of three
independent trials. Structures of the proposed degradation product are shown
below with the corresponding m/z values. The retention time and mass were
confirmed compared with the commercially available acid.
(C) Mtb-dependent degradation of C1 was monitored in representative resis-
tant mutants using a similar LC-MS-based assay as described above. Values
were calculated as percent C1 remaining relative to the concentration present
at 0 h. ETH, ethionamide. Bars represent mean ± SEM (n = 3). *p < 0.001; ns,
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streptomycin (Spies et al., 2008). We found that the recombi-
neered strains were resistant to C1, C2, and 4-AI but not to
isoniazid (INH) (Figure 3A), recapitulating our mutant MIC results
and establishing that these mutations were indeed responsible
for resistance.4 Cell Chemical Biology 28, 1–12, August 19, 2021Supplementing the growth medium with 1 mM of the products
of TrpA (indole), TrpB (L-Trp), or TrpE (anthranilate) rescued Mtb
from the inhibitory activity of the indole-4-carboxamides and
4-AI, increasing MICs 4- to 16-fold (Figure 3B). Interestingly,
addition of lower amounts of L-Trp (70 mM) had no effect on
the MIC. The ability of various primary metabolites to rescue
Mtb from growth inhibition by these compounds suggests that
4-AI is likely exerting a dominant pleiotropic effect on tryptophan
biosynthesis that is only overridden at high concentrations of
L-Trp. As a control, we utilized C5—an indoline-5-sulfonamide
compound (Figure 1B) that was previously reported to selectively
inhibit mycobacterial TrpAB (Abrahams et al., 2017). C5 potency
was significantly attenuated by exogenous indole or L-Trp (even
at 70 mM) but not by anthranilate; the result one would expect
from a compound like C5 that inhibits the final step of the
pathway. We therefore inferred that the indole-4-carboxamides
and 4-AI were unlikely to be acting as direct inhibitors of TrpAB.
Mutations in TrpE block feedback inhibition and
increase precursors of the pathway
The TrpE H170R mutant protein resulted in an approximately
4-fold shift in MIC for C1-C4 and 4-AI. To study the interaction
of these compounds with TrpE, we expressed and purified
both the TrpE WT and the TrpE H170R mutant proteins. An
in vitro enzyme assay showed that neither 4-AI (half-maximal
inhibitory concentration [IC50] = 6.2 ± 1.4 mM) nor C1 (IC50 =
242 ± 53 mM) inhibited TrpE at concentrations near their MICs
(Figure 4A), indicating that TrpE is not directly targeted by these
compounds. We compared the kinetic parameters of the WT
with the H170R mutant and found that, while a small change in
chorismate KM was found, it did not lead to a noticeable change
in catalytic efficiency, kcat (Figure 4B).
The crystal structure of Mtb TrpE shows that His170 is buried in
the TrpE homodimer interface and interacts with several residues
in the allosteric loop within the L-Trp binding site (Bashiri et al.,
2015). Previous studies have also shown thatmutations in the allo-
steric L-Trp binding site of TrpE lead to resistance against fluo-
roanthranilates and indole propionic acid (Negatu et al., 2019;
Zhang et al., 2013), which, like 4-AI, are structurally similar to
the intermediates of L-Trp biosynthesis. When we assayed the in-
hibition of TrpE, we found that the H170R mutant (IC50 = 221 ±
12 mM) was 250 times less sensitive to allosteric inhibition by
L-Trp than WT enzyme (IC50 = 0.87 ± 0.11 mM) (Figure 4C). This
suggests that the H170R mutation makes TrpE refractory to
feedback inhibition by L-Trp, which normally functions to restrict
flow of metabolites through the pathway. Therefore, this mutation
in TrpE enhances the flux of intermediates through the pathway
at L-Trp concentrations that would otherwise shut down
biosynthesis, allowing Mtb to overcome inhibition by 4-AI.
Discrete mutations in TrpAB determine the
resistance profile
None of the resistant mutants raised against C1 were cross-resis-
tant to C5 (Table 1); in fact, one C1Rmutant wasmore susceptible
to C5 relative to WT, suggesting a potential synergistic effect.
We independently raised resistant mutants against C5 and, in
agreement with previously published results (Abrahams et al.,
2017), we also found mutations in TrpAB (aP65L, aD136N,
bF188S, and bY200C). In a reciprocal experiment measuring the
Figure 3. Indole-4-carboxamides induce
perturbations in tryptophan biosynthesis
(A) Native copies of trpB and trpE in H37Rv were
replaced with mutant alleles identified from resis-
tant mutants via single-stranded DNA-mediated
recombineering. The activity of the compounds
was tested using a resazurin microtiter assay and
presented as percent viability relative to untreated
cells. INH, isoniazid.
(B) The MICs of the compounds were measured
with or without supplementation of the medium
with the indicated metabolite. Bars represent
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was observed (Table S4). Taken together, these results demon-
strate that, while independent TrpAB mutations confer resistance
to either C1 or C5, these two compounds have distinct mecha-
nisms of action. Substantiating this claim is a map of where the
mutated residues lie in the 3D structure of TrpAB. The mutations
that conferred resistance to C5 were found to cluster in the inter-
face between the a and b subunits, as reported for indolinesulfo-
namide-based (Abrahams et al., 2017) and azetidine-based
(Wellington et al., 2017) inhibitors that bind tightly to this region.
On the other hand, mutated residues conferring resistance
to C1 and 4-AI were scattered throughout the protein structure
(Figure 5A). Notably, bAla134 and bAla168 are located in helix 4
and strand 7, respectively, within the b subunit communications
domain—a region of the complex that mediates intersubunit allo-
steric cooperativity (Dunn, 2012). In the aobc inhibitor-bound
structure of Mtb TrpAB (PDB: 5TCI), aAsp54 is >22 Ǻ away fromCell Chethe a subunit catalytic residue aAsp68
(Bahar and Jernigan, 1999), while all TrpB
lesions are >10 Ǻ away from the catalytic
pyridoxal 50-phosphate cofactor. The loca-
tions of themutated residues easily explain
the lack of cross-resistance of the C1R
mutants to C5, and vice versa. Further-
more, the dispersed nature of the TrpAB-
mutated residues in the C1R mutants,
along with their sheer distance from the
subunit active sites, and the fact that a
specific TrpE lesion also confers resis-
tance, all suggest that the activity of 4-AI
may not be based on binding to and inhibi-
tion of a single enzyme. To confirm this, we
expressed and purified enzymatically
active forms of bothWT andmutant TrpAB
and studied their kinetics in vitro.
TrpAB mutants that confer
resistance to 4-AI have attenuated
enzymatic activity
To study the kinetics of the TrpAB com-
plex, we utilized a coupled enzyme assay
that detects the formation of G3P and
measured the kinetic parameters under
saturating IGP or L-Ser concentrations.We calculated an apparent KM
IGP = 76.9 ± 1.1 mM (Figure 5B),
and an apparent KM
LSer = 0.55 ± 0.23 mM (Figure 5C), in agree-
ment with previously reported values (Wellington et al., 2017);
and subunit catalytic efficiencies, kcat
a = 159.8 ± 9.7 min1 and
kcat
b = 94.8 ± 3.3 min1, indicating that the recombinant enzyme
was catalytically active. We found that 4-AI did not inhibit either
subunit (IC50
a = 630.7 ± 173.8 mM and IC50
b = 649.4 ± 2.5 mM) at
concentrations as low as that of the bona fide TrpAB inhibitor C5
(IC50
a = 0.10 ± 0.06 mM and IC50
b = 0.37 ± 0.07 mM) (Figures 5D
and 5E), confirming that the 4-AI whole-cell activity was not due
to inhibition of the final steps of L-Trp biosynthesis.
We studied the effect of representative mutations on the enzy-
matic activity of TrpAB to unravel the molecular basis of resis-
tance (Figures 5B and 5C). We selected the bA168V mutant
because this residue is located in the COMM domain—known
to coordinate catalysis in both subunits—and the bD261G
mutant, since this residue is located in an inconspicuous,mical Biology 28, 1–12, August 19, 2021 5
Figure 4. Resistance due to the TrpE H170R mutation results from
loss of allosteric feedback inhibition
(A) Inhibition of TrpE by C1 and 4-AI was studied in the presence of saturating
concentrations of chorismate (50 mM) and NH4
+ (100 mM). Inhibition is
reported as percent activity relative to the no inhibitor control.
(B) Steady-state kinetics ofWT TrpE and the H170R variant were studied under
varying chorismate concentrations by directly monitoring formation of the
fluorescent product, anthanilate.
(C) Allosteric feedback inhibition of TrpE WT and the H170R mutant was
measured under increasing concentrations of L-Trp and presented as percent
activity relative to the no L-Trp control. Data in all panels represent mean ±
SEM (n = 3).
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structural purpose. We find that both mutations effectively
decrease the catalytic activity of both the a and b subunits to
35%–45% of the WT (Figures 5F and 5G) when IGP was used
as a substrate. In addition, looking exclusively at the half-reac-
tion catalyzed by the b subunit (indole + L-Ser / L-Trp), we6 Cell Chemical Biology 28, 1–12, August 19, 2021observed the catalytic efficiency dropping 3-fold in the mutant
enzymes (Figures 5H and 5I). This suggested that attenuation
of enzymatic activity might result in evasion of the toxicity of
4-AI. This result is in contrast to canonical resistance mecha-
nisms against specific enzyme inhibitors, which typically involve
mutations resulting in either overexpression of the target (Larsen
et al., 2002; Park et al., 2017) or modification of the binding site
(Schaenzer andWright, 2020), both of which compensate for the
effect of the inhibitor by maintaining the concentration of the
enzymatic product to homeostatic levels.
4-AI is converted to 4-amino-L-Trp by TrpB
Motivated by the lackof enzymatic inhibition, and the fact that 4-AI
is an analog of indole, we explored the possibility of 4-AI being
incorporated into L-Trp biosynthesis by TrpB. We incubated puri-
fied TrpAB with 4-AI instead of indole under saturating L-Ser con-
centrations and observed the appearance of a product peak with
an m/z of 220, which we hypothesized was 4-amino-L-Trp (4-
aTrp) (Figure S2). To confirm that this new product was indeed
4-aTrp, we synthesized an authentic 4-aTrp standard by nitrating
L-tryptophan and separating theminor 4-nitro isomer after protec-
tion of the tryptophan amino group with a t-butoxycarbonyl group
(Figure S3). Following nitro reduction and deprotection we ob-
tained authentic 4-aminotryptophan and ran an LC-MS co-elution
assay (Figure 6A). We found that the chemically synthesized 4-
aTrp eluted at a retention time identical to that of the product of
the enzymatic reaction. In addition, spiking the enzyme reaction
with the synthetic 4-aTrp demonstrated co-elution. Furthermore,
the fragmentation pattern of the enzymatic product was indistin-
guishable from that of the chemical standard under various colli-
sion-induced dissociation potentials (Figures 6B, 6C, S4A, and
S4B). Together, these results indicate that the product peak
observed upon feeding TrpAB with 4-AI indeed corresponds to
4-aTrp, and that TrpB is capable of utilizing 4-AI as a substrate.
To study the kinetics of 4-AI utilization by the WT and the
mutant TrpAB, we incubated the recombinant enzymes with
increasing 4-AI concentrations (under a saturating L-Ser con-
centration) for 5 min, quenched the reaction with 0.1% formic
acid in methanol, and detected the formation of 4-aTrp via
LC-MS. The kcat values for the b reaction for the WT enzyme
with 4-AI (Figure 6E) appeared to be about twice that of the cor-
responding b reaction for the native indole substrate (Figure 5I).
We found that both TrpABmutants utilize 4-AI less efficiently as a
substrate compared with the WT enzyme (Figures 6D and 6E),
similar to the effect observed when indole is used as a substrate
(Figure 5I). Therefore, these mutations decrease the incorpora-
tion of 4-AI, potentially reducing the toxicity of the resulting
4-aTrp and imparting resistance to the cell. In a scenario where
TrpB uses 4-AI, the cell would require higher levels of exogenous
L-Trp to minimize and compete with the buildup of endogenous
4-aTrp, retrospectively explaining why 1 mM (but not 70 mM) of
L-Trp was required to rescue the growth of Mtb in the presence
of 4-AI (Figure 3B).
Finally, we incubated Mtb with 4-AI for 24 h under conditions
that would promote incorporation and minimize cell death
(103 MIC with Mtb at an optical density at 600 nm [OD600] =
3.0). We then extracted the metabolites in Mtb using 1:1 ACN:
MeOH and injected aliquots in the LC-MS. We detected forma-
tion of 4-aTrp in WT cells (Figure S5) indicating that, in a cellular
Figure 5. Resistance due to TrpAB mutations result from attenuation of enzymatic activity
(A) 3D crystal structure of Mtb TrpAB with bound inhibitor (BRD4592, PDB: 5TCI) showing the location of the resistance-conferring mutations. The a subunit is
shown in yellow, the b subunit in cyan. Mutations in C1R strains are shown in red, while mutations in C5R strains are shown as magenta.
(B and C) Fluorometric determination of the steady-state kinetics of WT and mutant TrpAB (IGP + L-Ser / G3P + L-Trp) under saturating L-Ser (B) or IGP (C)
concentrations. Data shown are mean ± SEM (n = 3).
(D) Inhibition of the TrpAB a reaction was monitored by coupling the IGP consumption to the spectrophotometric detection of the liberated G3P. Data are mean ±
SEM (n = 2).
(E) Inhibition of the TrpAB b reaction (using indole as substrate) measured by monitoring the change in absorbance due to formation of L-Trp. Data represent
mean ± SEM (n = 3).
(F and G) Catalytic efficiency, kcat, of TrpAB a subunit (F) and b subunit (G) in theWT andmutant enzymes calculated from the Michaelis-Menten curves in (B) and
(C), respectively. Bars represent mean ± SEM (n = 3). *p < 0.05, **p < 0.001 when compared with the corresponding WT kcat using one-way ANOVA.
(H) Spectrophotometric determination of the kinetics of the b half-reaction (indole + L-Ser / L-Trp) of the WT (50 nM) and mutant (200 nM) TrpAB. Data are
mean ± SEM (n = 2).
(I) Calculated catalytic efficiencies for the b half-reaction of the WT and mutant TrpAB from (H). Bars represent mean ± SEM (n = 2). *p < 0.05, **p < 0.01 when
compared with the WT kcat using one-way ANOVA.
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thetic pathway. The 4-aTrp concentration within the TrpAB
bA168V-resistant mutant were significantly reduced compared
with WT (Figure 6F) in agreement with the marked decrease in
enzymatic catalysis we observed in vitro. Finally, in the TrpE
H170R-resistant mutant, we detected 4-aTrp levels higherthan in the TrpAB mutant but lower than in the WT. We
hypothesized that 4-aTrp could also allosterically inhibit TrpE,
restricting flow of metabolites and decreasing 4-AI incorpora-
tion, resulting in lower intracellular 4-aTrp concentration.
However, when we measured the ability of 4-aTrp to affect allo-
steric inhibition of TrpE we found inhibition only with an IC50Cell Chemical Biology 28, 1–12, August 19, 2021 7
Figure 6. TrpB converts 4-AI to 4-amino-L-Trp in vitro and in Mtb
(A) Representative chromatograms of synthetic 4-aTrp (red trace), the enzymatic reaction mixture obtained by incubating TrpAB with 4-AI (blue trace), and the
enzyme reaction spiked with synthetic 4-aTrp (black trace).
(B and C) Fragmentation pattern of synthetic 4-aTrp (B) and the enzyme reaction mixture (C) in a triple quadrupole mass spectrometer.
(D) 4-AI was incubated with WT or mutant TrpAB in the presence of saturating L-Ser concentrations. The resulting 4-aTrp was quantified using LC-MS.
Data shown are mean ± SEM (n = 2).
(E) Calculated catalytic efficiency, kcat, of the WT and mutant TrpAB in (D). Bars represent mean ± SEM (n = 2). *p < 0.05, **p < 0.01 when compared with the WT
kcat using one-way ANOVA.
(F) Intracellular 4-AI incorporation into 4-aTrp was measured by extracting the metabolites using 1:1 ACN:MeOH. The concentration of 4-aTrp produced within
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alleviate allosteric regulation (IC50 versus TrpE H170R = 63.6 ±
8.3 mM) (Figure S6). While directly correlating the in vitro IC50
with the apparent IC50 against TrpE within Mtb cells is impos-
sible, the relatively high in vitro IC50 suggests that 4-aTrp8 Cell Chemical Biology 28, 1–12, August 19, 2021generated by TrpB is unlikely to feedback inhibit TrpE and shut
down overall L-Trp biosynthesis. Exogenously added synthetic
4-aTrp did not have any antitubercular activity (MIC > 100 mM),
but transport of this molecule into Mtb cells may not be very effi-
cient. Incubating Mtb cells with 10 or 100 mM 4-AI over a 3-day
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(Figure S7) showed that the intracellular L-Trp pool is unaffected
by exogenous 4-AI. Furthermore, intracellular 4-aTrp levels rose
to nearly ten times that of endogenous L-Trp levels, which re-
mained under 5 mM over the same time period, indicating that
the 4-AI cytotoxicity is likely due to intracellular accumulation
of 4-aTrp that eventually gets incorporated into native proteins
rather than L-Trp starvation. It should be noted that incorporation
of fluorotryptophans into native proteins has been previously
observed in M. smegmatis (Nurul Islam et al., 2019).
DISCUSSION
Our study showed three distinct mechanisms of Mtb resistance
to indole 4-carboxamides. First, loss-of-function mutations in
AmiC result in diminished hydrolysis of C1 and therefore no
4-AI—the active component—is liberated. In TB drug discovery,
the shift to whole-cell screening followed by target deconvolu-
tion by whole-genome sequencing of resistors has identified
many enzymes that metabolize drugs (Grant et al., 2016).
Many of these ‘‘activating’’ enzymes are encoded by non-essen-
tial, dispensable genes resulting in high frequencies of resis-
tance. Indeed, we picked up amiC mutations at a frequency of
106, 100-fold more common than the frequency of trpABEmu-
tations. The frequency of resistance was dependent on the size
of the inoculum; thus, when 109 cells were plated, there were
probably enough bacilli on the plate to hydrolyze all C1 to 4-AI,
and we were inadvertently raising mutants against 4-AI.
Whereas, when 107 cells were plated, hydrolysis may not have
been as extensive; hence, the mutants were selected against
the parent compound C1. AmiC-mediated hydrolysis must
have a certain degree of substrate promiscuity since derivatives
that varied greatly in the size, polarity, and position of the
carboxylic acid coupling partner relative to indoleamine dis-
played low mM MICs against Mtb (compounds C16-C21 in
Table S3). It may also be possible that AmiC can mediate the
hydrolysis of other potential antimycobacterial amides.
The second resistance mechanism we described here is a
specific mutation in TrpE that makes the enzyme resistant to
allosteric feedback inhibition by L-Trp—a phenomenon repeat-
edly observed in Mtb (Negatu et al., 2019; Zhang et al., 2013).
This effectively keeps a steady flux of intermediates through
the pathway under L-Trp concentrations that would normally
shut down biosynthesis. A TrpEmutation that would prevent pre-
maturely shutting down the entire pathway therefore will allow
Mtb to produce enough L-Trp to a sufficient level to effectively
compete with endogenous 4-aTrp for protein incorporation,
overcoming the 4-AI-imposed L-Trp starvation. The results we
obtained when the growth medium was supplemented with
metabolic intermediates downstream of TrpE (Figure 3B) sup-
port the notion that maintaining or increasing the flux through
the pathway will ‘‘dilute’’ the toxic effects of 4-aTrp buildup.
Previously, 5-fluorotryptophan (produced from the incorporation
of 5-fluoroanthranilate) was shown to also allosterically inhibit
TrpE with an IC50 of 4 mM (Negatu et al., 2019)—an unsurprising
result given the conservative nature of the hydrogen-to-fluorine
substitution. Here, we show that the IC50 of 4-aTrp against
TrpE is 15-fold higher, indicating that small alterations in the
L-Trp structure can have a large effect in TrpE inhibition.The final mechanism of resistance we uncovered in this study
involves the alteration of TrpAB enzymatic activity that effectively
decreases conversion of 4-AI to 4-aTrp while simultaneously
decreasing the indole to L-Trp conversion as well. The TrpAB
mutants grew equally well as the WT in rich media, indicating
that the resistors had an exquisitely fine-tuned TrpAB activity,
effectively lowering 4-AI incorporation while still satisfying
nutritional requirements tomaintainWT-like growth. The demon-
stration that, under homeostatic conditions, de novo L-Trp
biosynthesis in Mtb only generates a small pool of L-Trp
(cytosolic concentration <5 mM) (Agapova et al., 2019), coupled
with the fact that Trp is one of the least-abundant amino acids in
proteins (only accounting to ~1%) explains why even a weak-
ened TrpAB is still able to meet the L-Trp demands of the cell.
The TrpAB mutations we found were scattered throughout the
protein structure, with two lesions located in the b subunit
COMM domain. Throughout the catalytic cycle of TrpAB, the
two subunits interact largely through the COMM domain
(Dunn, 2012), which also creates part of the tunnel where indole
produced from the a subunit is presumably shuttled through to
reach the b subunit active site (Hilario et al., 2016). Therefore, it
is expected that the bA168V mutation will result in faulty catal-
ysis. On the other hand, why the bD261G mutation—a residue
that lies in an inconspicuous location of the complex that
has no annotated catalytic or cooperative function—leads to
catalytic attenuation is still a mystery. We note that the
bD261G mutation potentiates the activity of the validated TrpAB
inhibitor (C5), rendering the mutant more susceptible to C5
compared with the WT (Table 1).
In this work, we describe a series of indole-4-carboxamides
that, upon AmiC-mediated hydrolysis, liberate 4-AI, which gets
incorporated into the L-Trp biosynthetic pathway to form
4-aTrp. The tolerance of the L-Trp biosynthetic enzymes in
Mtb is demonstrated by a recent study that shows that
fluoroanthranilates produce fluorotryptophans, but none of the
fluorinated intermediates (Nurul Islam et al., 2019), indicating
that all enzymes within the pathway accommodate minor
substrate modifications and that fluorinated derivatives are
incorporated through this pathway. Furthermore, the substrate
promiscuity of TrpB (either isolated from other bacteria or opti-
mized through directed evolution) has been exploited by chem-
ists to enantioselectively synthesize a variety of L-Trp analogs
that would otherwise be difficult to access (Buller et al., 2015;
Romney et al., 2017; Winn et al., 2018). Small-molecule probes
that harness the natural TrpB reactivity without significant
cellular toxicity could, in theory, be used tomonitor L-Trp biosyn-
thesis in real time under various conditions and begin to answer
why L-Trp starvation has a cidal effect in Mtb. It is logical to as-
sume that various substituted L-Trp derivatives can also be
incorporated into proteins via the action of equally promiscuous
aminoacyl tRNA synthetases (Brustad et al., 2008); but how the
structure and activity of these proteins will change in the pres-
ence of L-Trp analogs remains to be demonstrated. Biochemical
analyses show that 4-aTrp in fluorescent proteins introduces sig-
nificant pH sensitivity at the expense of protein stability (Budisa
and Pal, 2004), and similar changes can be expected with myco-
bacterial proteins.
Even though TrpB can utilize an assortment of indole substi-
tutions, the downstream effects of the substituted tryptophansCell Chemical Biology 28, 1–12, August 19, 2021 9
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that would liberate 5- and 6-aminoindole were inactive, while
those that liberate 7-aminoindole had only weak activity
(compounds C6-C8 in Table S3). Similarly, 4-fluoroanthranilate
was also more toxic to Mtb compared with the 5- and
6-substituted version (Nurul Islam et al., 2019). Furthermore,
derivatives that would liberate 4-substituted N-methylindoles,
indolines, or indazoles were all inactive against Mtb (com-
pounds C9-C15 in Table S3). Therefore, there appears to be
an inherent toxicity associated with L-Trp substituted at the
4-position. Complicating the situation is the possibility that
toxicity may not be a direct result of incorporation into proteins.
A global replacement of all L-Trp residues in a fluorescent pro-
tein found that, while 4- and 5-aTrp were quantitatively incorpo-
rated, there was no assimilation observed for 6- and 7-aTrp
(Budisa et al., 2002).
In mycobacteria, previously demonstrated metabolic changes
that confer drug resistance involve one of several mechanisms,
including (1) overexpression of the target to overcomemetabolic
blockage by stoichiometrically limiting the number of enzymes
deactivated by the drug (Park et al., 2017). (2) Using a compen-
satory pathway that bypasses the inhibited stepwhile preserving
the generation of the end product (Lamprecht et al., 2016). (3)
Loss of function in an enzyme that catalyzes the opposing reac-
tion of the target (Ballinger et al., 2019). A definitive demonstra-
tion of resistance acquisition through alteration of substrate
recognition or enzymatic attenuation is lacking in the literature.
In a similar sense, 5-fluorouracil (5-FU) was shown to be a meta-
bolic poison in Mtb—being incorporated into cellular DNA and
RNA (Singh et al., 2015). Single-nucleotide insertions in
rv3309—encoding for one of the two uridine phosphoribosyl-
transferase in Mtb—was found in one group of 5-FUR mutants.
5-FU was subsequently shown to be utilized by Rv3309 as a
substrate in the biosynthesis of fluoro-UMP. Therefore, loss-of-
function mutations in rv3309 abrogated incorporation of 5-FU
and resulted in resistance—a similar phenotype to that observed
in our TrpAB mutants.
In conclusion, we demonstrated the mechanism of action of
indole-4-carboxamides and the molecular basis of Mtb resis-
tance against these compounds. We validated the idea that
modulation of metabolism—either by maintaining flux through
resistance from feedback inhibition (mutation in TrpE) or
reducing flux through enzymatic attenuation (mutations in
TrpAB)—affords antimicrobial resistance in Mtb. Poisoning
tryptophan metabolism by deliberately engineering novel
prodrugs of 4-AI with suitable pharmaceutical properties repre-
sents a promising avenue for the development of a novel
antituberculosis agent.
SIGNIFICANCE
With the rise of multidrug-resistant Mycobacterium tuber-
culosis (Mtb) comes the urgent need to identify potential
new drug targets. Tryptophan biosynthesis has previously
been identified as a potent target for chemotherapy due
to synergistic effects with current drug regimens.
Here, we describe the mechanism of action of a series of
antimycobacterial indole-4-carboxamides and the result-
ing mechanism of resistance Mtb deploys to subvert their10 Cell Chemical Biology 28, 1–12, August 19, 2021cidal effect. We found the series of indole-4-carboxamides
to be prodrugs of an antimetabolite, 4-aminoindole, which
becomes metabolically incorporated by tryptophan syn-
thase to form the cytotoxic 4-aminotryptophan. Mtb
acquired resistance by deploying three discrete mecha-
nisms (1) decrease in drug metabolism, (2) increased
biosynthetic flux of tryptophan, and (3) in situ enzymatic
attenuation of tryptophan synthase. This third method, we
propose to be a bona fide resistance mechanism in
mycobacteria. Ultimately, these results further demon-
strate the complexity involved in Mtb modulation of
tryptophan biosynthesis and enhance our understanding
of this valuable drug target.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Bacterial strains and culture conditions
M. tuberculosis and M. bovis were obtained from laboratory stocks. M. tuberculosis H37Rv or mutants thereof were used for all
experiments. Liquid media used most often is 7H9/Gcas (4.7 g/L Middlebrook 7H9 broth base, 4 g/L glucose, 0.8 g/L NaCl,
0.3 g/L Casitone, and 0.05% Tyloxapol), referred to as BSA-free media in the main text. Some MIC measurements were also
done in 7H9/ADC (4.7 g/L 7H9 broth base, 5 g/L BSA fraction V, 2 g/L glucose, 0.81 g/L NaCl, 0.02% glycerol, and 0.05% tween
80) or GAST-Fe medium (0.3 g Bacto Casitone (Difco), 4.0 g K2HPO4, 2.0 g citric acid, 1.0 g L-alanine, 1.2 g MgCl2 6H2O, 0.6 g
K2SO4, 2.0 g NH4Cl, 1.80 ml 10 NaOH, 10.0 ml glycerol, 0.05% Tween 80 and 0.05 g ferric ammonium citrate adjusted to pH 6.6).
Solid medium used where appropriate was Middlebrook 7H11 agar supplemented with 5 g/L dextrose, 2 g/L NaCl, 0.5% glycerol,
and 0.06% oleic acid (collectively called 7H11/OADC).
Primers and plasmids
All primers used in this studywere obtained fromEurofins in their dry and desalted form and reconstituted (as received) in 1X TE buffer
to make 100 mM stocks and further diluted in mQ H2O to 10 mM. The 10 mM solutions were used for all cloning protocols. All cloning
protocols and plasmid isolations were done using commercially available kits from Zymo Research Company.
METHOD DETAILS
Minimum inhibitory concentration
The antimicrobial susceptibility testing againstM. tuberculosis andM. boviswere performed in 7H9/ADC, while those for the resistant
mutants (and the correspondingWT control) were done in 7H9/Gcas. Bacteria were grown in the correspondingmedia up to anOD600
of 0.2 to 0.4. A two-fold serial dilution series (50 mL) of the test compounds was placed in each well of a sterile 96-well round bottom
plate, and then 50 mL of the bacterial suspension diluted to OD600 of 0.0002 was added. The plates were incubated at 37
C for
2 weeks prior to visual determination of the MIC. The MIC is defined here as the drug concentration that completely inhibited growth
of cells. MICsmeasured in the presence of supplementationwere done by supplementing the growthmediumwith 1mM (or 70 mM) of
the corresponding metabolite.e2 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
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For the ex-vivo efficacy testing, J774.1 cells (2x105 cells/well) were seeded in flat-bottom 24-well plates (Corning Inc.) in DMEM
GlutaMAX supplemented with 10% FBS, 20 mM HEPES, and 0.5 mM sodium pyruvate (hereafter abbreviated as DMEM/FBS).
The cells were infected with M. tuberculosis H37Rv (1x106 cells/well, MOI 1:5) for 24 hrs, followed by removal of the medium and
washing twice with Dulbecco PBS. Infected cells were exposed to test compounds at the specified concentrations in fresh growth
medium (1 mL/well). Cells were incubated at 37C, 95% humidity, 5% CO2 incubator for 7 days. The medium was changed every
2 days and the infected cells were treated with a fresh batch of drugs each time. After 7 days of incubation, themediumwas removed
and the cells were washed with PBS twice. Then, 500 mL of 0.1%SDSwas added to each well to lyse the J774 cells. After 5 mins, the
lysate was thoroughly mixed and diluted in 7H9/ADC and appropriate dilutions were plated in duplicate on 7H11/OADC plates to
calculate the most probable number of bacteria. Colonies were counted manually in each plate following 6-8 weeks of incubation
at 37C.
J774.1 cytotoxicity
The in vitro cytotoxicity of the indole-4-carboxamides were measured in DMED supplemented with 10% FBS. 1x104 J774.1 cells
were seeded onto each well of a sterile opaque 96-well plate and left to attach overnight. The next day, the media was aspirated
and replaced with a two-fold serial dilution of compounds in the same media. The cells were treated for 24 hrs prior to viability
determination using CellTiter-Glo (Promega) according to the manufacturer instructions.
Resistant mutant isolation
To raise resistant mutants against compound C1, 107, 108, and 109 cells ofM. tuberculosisH37Rvwere plated on 7H11/OADC plates
containing 5x the in vitro MIC of C1. Drug-free plates were used to enumerate bacterial load. The plates were incubated at 37C for
4-6 weeks until colonies grew to an appreciable size. The colonies were picked and inoculated into drug-free 7H9/Gcas medium and
the MIC were tested (according to the above protocol) to confirm true resistance against C1. The genomic DNA of the mutants were
isolated using the CTAB method (Park et al., 2017) and were sequenced and analyzed as previously described (Ioerger et al., 2010).
Cloning of AmiC into pMV306
Themycobacterial shuttle vector pMV361 (Stover et al., 1991) was derivatized in house to generate a non-integrative overexpression
vector. The backbone of plasmid pMV361 was amplified using primers 1001 (F) and 1002 (R) (see Table S5), digested with NcoI and
reannealed, in order to introduce an NcoI restriction site at the translational start site and simplify future cloning steps. The L5
integrase was removed using primers 1003 (F) and 1004 (R) with terminal BamHI restriction sites. Furthermore, the hsp60 promoter
(Stover et al., 1991) was exchanged with Psmyc from pML1357 (Huff et al., 2010) exploiting the XbaI and NcoI restriction sites using
primers 1005 (F) and 1006 (R). The new plasmid was named pL5-Psmyc. The amiC gene was amplified fromM. tuberculosis H37Rv
genomic DNA using primers 1007 (F) and 1008 (R) and the Q5 Hot-start high-fidelity 2X Master Mix (New England Biolabs). The
amplicon and pL5-Psmyc was double digested with NcoI and ClaI; the vector was also treated with alkaline phosphatase (CIP,
New England Biolabs) for 30 mins. The DNA fragments were gel purified and the amiC fragment was ligated to the vector backbone
overnight at room temperature using T4 DNA ligase (New England Biolabs). The ligation reaction was transformed into E. coli NEB5a
competent cells and the transformants were plated on LB agar containing 50 mg/mL kanamycin. Positive transformants were grown
and the plasmid was extracted and confirmed by Sanger sequencing (Eurofins).
Overexpression of AmiC in M. tuberculosis H37Rv
Electrocompetent M. tuberculosis H37Rv (400 mL) were transferred into a 2mm-gap electroporation cuvette and mixed with 1 mg of
pL5-Psmyc-AmiC. The cells were electroporated using a Bio-Rad GenePulser II electroporator set at the following paramters: 2.5 kV,
1000U, 25 mF. Immediately after electroporation, 1mL of 7H9/ADCwas added to the cells and themixture was transferred into 10mL
of sterile 7H9/ADC and the cells were allowed to recover for 24 hrs at 37C. The cells were diluted and plated into 7H11/OADC plates
containing 25 mg/mL kanamycin and incubated at 37C for 4-6 weeks. Electroporation using an empty vector was used as control.
The resulting colonies were grown in 7H9/GCas containing 25 mg/mL kanamycin and the MICs were measured using the protocol
described above.
Compound metabolism in H37Rv
To determine the degree of drug metabolism in live M. tubeculosis and the C1R mutants, an LC-MS-based protocol was employed.
The cells were grown in 7H9/Gcas to an OD600 of 1.0, washed twice with PBS, and resuspended in PBS at 1/3 the original culture
volume to afford a suspension at OD600 of 3.0. Then, 1mL of the cell suspension was added to enough compound in DMSO to create
a final compound concentration at 10X the in vitro MIC. A 200 mL aliquot was removed for the 0 hr time point (immediately after
addition of the cells to the drug) and mixed with an equal volume of acetonitrile (ACN) and kept at 4C. After 24 hrs, another
200 mL aliquot was removed and mixed with ACN. The cells in these aliquots were pelleted and the supernatant was filtered through
a 0.2 mmcentrifuge filter prior to taking the samples out of the BSL3. A 20 mL aliquot was injected directly into the LC-MS. LC gradient
used to separate the metabolites was 5-95% ACN over 20 mins. Chromatograms obtained at 270 nm were used to determine %
compound remaining after 24 hrs, and were normalized relative to the 0 hr time point.Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021 e3
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M. tuberculosis (100 mL) was grown up in 7H9/ADC to an OD600 of 0.8. Cells were harvested, washed twice with 20 mL PBS and
resuspended in 5.6 mL modified Sauton’s medium. The Sauton’s medium consisted of magnesium sulfate heptahydrate (0.5 g/L),
potassium dihydrogen phosphate (0.5 g/L), potassium sulfate (725 mg/L), citric acid (2 g/L), ferric ammonium citrate (50 mg/L),
L-asparagine (4 g/L), zinc sulfate (0.1 mg/L), glycerol (20 g/L), with pH adjusted to 6.5 with sodium hydroxide (10 M). Half of the
cell suspension was treated with 100 mM of 4-aminoindole and the other half with an equivalent amount of DMSO. The samples
were divided into 600 mL aliquots and incubated at 37C in a shaking incubator with 600 mL acetonitrile added at the indicated
time points. Samples were stored at -80C prior to further processing. In a separate experiment,M. tuberculosis (700 mL) was grown
up in 7H9/Gcas to an OD600 of 0.5. Cells were harvested, washed and treated with 10 mM and 100 mM of 4-aminoindole as above
and quenched with 600 mL acetonitrile prior to storage at -80C.
For tryptophan and 4-aminotryptophan concentration determination (Widner et al., 1997), a stock solution of 3-nitrotyrosine as
internal standard, (IS) in 1% heptafluorobutyric acid (HFBA) wasmade and 20 mL IS solution was added to 200mL sample /acetonitrile
mix. Samples were centrifuged to remove precipitant. Concentrations were determined by an Agilent 1290 Infinity HPLC with an
Agilent 6460C triple quadrupole mass selective detector. Separation was achieved on an Agilent Eclipse Plus C18 1.8 mm column
(dimensions 2.0 x 50 mm) with mobile phase A being aqueous 0.1% HFBA and B being acetonitrile with 0.1% HFBA. 0.8 mL/min
flow rate was applied with 7% B starting gradient held 0.25 min, then ramped to 95% B over 4.75 min. Detection was achieved in
multiple reaction monitoring mode (MRM) using electrospray ionization with capillary voltage of 2000V and nitrogen gas in collision
cell. Tandem mass ions for each precursor M+H+ adduct were detected with the product ions m/z 157.1 (CEV 20), 188 (CEV 7), and
181.1 (CEV 10) for 4-aminotryptophan, tryptophan, and IS respectively (CEV = collision energy voltage in volts).
Mycobacterial recombineering
To replace the native copies of trpB and trpE with the mutant alleles, a previously described single-stranded DNA-mediated
recombineering protocol was employed (Murphy et al., 2015). 70-mer oligonucleotides were designed to introduce the specific
mutations in H37Rv (primers 1009 – 1012 in Table S5). M. tuberculosis carrying pKM402 plasmid was grown to OD600 of ~ 1.0 in
7H9/ADC. The culture was subcultured to an OD600 of 0.1 in 30 mL 7H9/ADC containing 20 mg/mL kanamycin and the cells were
allowed to grow to an OD600 of ~0.8. RecT expression was induced by addition of anhydrotetracycline (aTc) to a final concentration
of 500 ng/mL and allowing the cells incubate overnight at 37C. Then, 3 mL of a 2M sterile glycine solution was added and the cells
were incubated for an additional 16 hrs at 37C. The cells were collected and washed twice with 10% glycerol and finally
resuspended in 3 mL of sterile 10% glycerol. 400 mL of the electrocompetent and recombinogenic M. tuberculosis were transferred
to a 2mm-gap electroporation cuvette, into which 500 ng of oligos were added. The cells were electroporated using a Bio-Rad Gene
Pulser II set at the following parameters: 2.5 kV, 1000 U, 25 mF. The cells were removed from the electroporation cuvette and added
to 10 mL of 7H9/ADC and allowed to recover at 37C for 3 days. Then the cells were subcultured 1:100 into 7H9/ADC containing
20 mg/mL kanamycin and allowed to grow to an OD600 of ~1.0. The cells were diluted and finally plated on 7H11/OADC plates
containing 20 mg/mL streptomycin and incubated at 37C for 4-6 weeks. Several clones for each recombineering target were
selected and genomic DNA was extracted using the CTAB method. The clones were screened for the desired mutations via PCR
using primers 1013 – 1018 (see Table S5) followed by Sanger sequencing of the PCR products.
Resazurin broth microdilution assay
The resistance of the recombineering andWT strain against NMMV03 compounds were measured using the Alamar Blue Assay. The
bacterial strains were grown in 7H9/GCas and the susceptibility testing were done according to the MIC protocol described above.
After 7 days of drug treatment, 10 mL of Alamar Blue (ThermoFisher) was added to each well and the plates were returned to the 37C
incubator for 24 hrs. The fluorescence (lex = 530 nm, lem = 590 nm) was read using a ClarioStar multiwell plate reader. The
fluorescence of the treated wells were normalized to that of the corresponding untreated well and presented as % cell viability.
Cloning, expression and purification of Mtb TrpE
TheM. tuberculosisH37Rv trpE genewas amplified from a genomic DNA template using theQ5Hot Start High-Fidelity 2XMasterMix
(New England Biolabs) and primers 1019 (F) and 1020 (R). The trpE amplicon was cloned between the NdeI and HindIII sites of
pET28a, resulting in an N-terminal His6 tag. The PCR product and pET28a were separately digested with NdeI and HindIII and ligated
overnight at room temperature using T4 DNA ligase. The ligation mixture was directly transformed into E. coliNEB5a competent cells
and the cells were plated onto LB agar + 50 mg/mL kanamycin. The plasmid was extracted and analyzed by Sanger sequencing. To
introduce the H170R, the Q5 site-directed mutagenesis kit (New England Biolabs) was used using the pET28a-TrpE construct as
template. Primers 1021 (F) and 1022 (R) were used and the resulting Q5 product was transformed into competent NEB5a cells.
The H170R mutation was confirmed by Sanger sequencing. The pET28a-TrpE WT and H170R plasmids carrying the correct
sequence were then transformed into competent E. coliBL21(DE3) and the transformants were plated onto LB agar plates containing
50 mg/mL kanamycin. Positive transformants were inoculated into 20 mL LB + 50 mg/mL kanamycin and grown overnight. The entire
overnight culture was transferred into 2 L of LB containing 50 mg/mL kanamycin and allowed to grow until OD600 of ~0.6. Protein
expression was induced by addition of IPTG to a final concentration of 1 mM. The cells were incubated for an additional 3 hrs at
37C prior to harvesting by centrifugation at 4000xg for 10 mins. The cells were resuspended in 30 mL of lysis buffer (50 mM Tris-
HCl, pH 8.0; 500 mM NaCl, 5 mM imidazole, and 1X protease inhibitor cocktail (tablets from Roche)) and disrupted via sonicatione4 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
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onto a Ni-NTA column equilibrated with 25 mL of column buffer (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 mM EDTA, 5 mM
imidazole). The column was washed with 30 mL of column buffer with increasing imidazole concentrations (5 mM, 10 mM,
20 mM, and 40 mM imidazole). The protein was eluted using 10 mL of column buffer containing 300 mM imidazole and collected
in 1mL fractions. The fractions containing purified TrpE (as seen from aCoomassie-stained polyacrylamide gel) were pooled together
and concentrated to ~2.5 mL. The protein was buffer exchanged using a PD-10 (Sigma-Aldrich) column equilibrated using 30 mL of
storage buffer (20 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, and 5% glycerol) and eluted from the PD-10 column using 3 mL of
storage buffer. The protein was split into 300 mL aliquots and flash frozen using a dry ice/isopropanol bath and stored at -80C until
use. The concentration of the protein preparations was established using the Pierce BCA Assay kit (ThermoFisher) using BSA as a
standard, and the concentrations were converted to mM using the calculated molecular weight of TrpE WT and H170R.
Mtb TrpE enzyme assay and inhibition studies
The TrpE enzyme kinetics were studied by direct detection of the fluorescent product, anthranilate at lex = 320 nm and lem = 460 nm
using a ClarioStar multiwell plate reader. The total volume was 200 mL in all cases and the assay buffer used contained 20 mM Tris-
HCl pH 8.0, 100 mM NH4Cl, 10 mM MgCl2, 100 mM EDTA. The Michaelis-Menten curves were obtained by incubating the enzyme
with increasing concentrations of chorismate (dissolved in the assay buffer) where the reaction was started by addition of 0.67 mMof
TrpE WT or the H170R mutant. For the inhibition studies, a fixed 50 mM chorismate concentration was used, and increasing
concentration of the drugs or L-Trp was added. The fluorescence of anthranilate was converted into concentration values using a
standard calibration curve prepared in the same buffer used for kinetic studies. The kcat, and IC50 values were all calculated using
nonlinear curve fitting in GraphPad Prism 8.
Cloning and site-directed mutagenesis of Mtb TrpAB
The TrpAB enzyme complex were co-expressed using the pRSFDuet-1 vector tagging TrpB with an N-terminal Hi6 epitope in MCS1
and cloning TrpA in MCS2. trpBwas amplified from H37Rv genomic DNA using primers 1023 (F) and 1024 (R) and Q5 Hot-start high-
fidelity 2X master mix (New England Biolabs). The amplicon and pRSFDuet-1 were digested with HindIII for 1 hr; the vector was also
treated with alkaline phosphatase (CIP, New England Biolabs) for 30 mins. The DNA fragments were gel purified and ligated using T4
DNA ligase (New England Biolabs) overnight at room temperature. The ligation mixture was transformed into competent E. coli
NEB5a cells, the plasmid was extracted, and the sequence was verified using Sanger sequencing (Eurofins). Then, trpA was cloned
into pRSFDuet-TrpBMCS1 in a similar manner between the NdeI and XhoI sites. The resulting pRSFDuet-TrpBMCS1-TrpAMCS2
construct was fully sequence to verify the sequence of both coding regions and the overall integrity of the plasmid. Initial expression
studies in BL21(DE3) cells using this construct showed significant difference in the expression level between TrpB and TrpA
(~5:1 TrpB:TrpA).
To increase expression of TrpA, we prepared another construct and co-introduced the two plasmids into the expression vector.
The TrpA supplemental expression plasmid was also made using the pRSFDuet-1 vector. Briefly, the native KanR marker of
pRSFDuet-1 was replaced by amplifying the AmpR cassette from pUC19 using primers 1027 (F) and 1028 (R) and cloning the
amplicon between the AgeI and SphI restriction sites of pRSFDuet-1. The resulting pRSFDuetAmpR was used as a backbone for
TrpA. TrpA was amplified from H37Rv genomic DNA using primers 1029 (F) and 1030 (R) and Q5 Hot-start high-fidelity 2X master
mix (New England Biolabs). The amplicon and pRSFDuetAmpR was double digested with NcoI and HindIII; the vector was also treated
with alkaline phsphatase (CIP, New England Biolabs). The DNA digests were gel purified and ligated using T4 DNA ligase (New
England Biolabs) overnight at room temperature. The ligation was transformed into competent E. coli NEB5a cells and plated on
LB agar containing 100 mg/mL Ampicillin. The positive transformants were grown, the resulting plasmid (pRSFDuetAmpR-TrpAMCS1)
extracted and analyzed by Sanger sequencing (Eurofins).
To introduce the bA168V and the bD261G mutations, the Q5 site-directed mutagenesis kit (New England Biolabs) was used using
the pRSFDuet-TrpBMCS1-TrpAMCS2 construct as template. Primers pairs 1031 (F) – 1032 (R) and 1033 (F) – 1034 (R) were used and the
resulting Q5 product was transformed into competent NEB5a cells. Introduction of the mutations were confirmed by Sanger
sequencing (Eurofins).
Overexpression and purification of Mtb TrpAB
Competent E. coli BL21(DE3) were co-transformed with pRSFDuet-TrpBMCS1-TrpAMCS2 and pRSFDuetAmpR-TrpAMCS1 and grown in
LB + 50 mg/mL kanamycin and + 100 mg/mL ampicillin. The transformed BL21(DE3) cells were grown in LB media at 37C until an
OD600 of 0.6-0.7. Expression was inducedwith IPTG (1mMfinal concentration) and incubated for 3 hours at 37
C. Cells were pelleted
by centrifugation at 4000rpm for 20 minutes and then resuspended in lysis buffer (50 mM HEPES pH 8.0, 150 mM KCl, 5% glycerol,
10 mM Imidazole, 1 mM PLP, 1 mM TCEP, and 1X Protease Inhibitor Cocktail Tablet (Roche)). After sonication, the lysed cells were
pelleted by centrifugation at 15,000 rpm for 60 minutes. The supernatant was loaded onto a Ni-NTA column, and then washed with a
wash buffer (50mM HEPES pH 8.0, 100mM KCl, 5% glycerol, 1 mM PLP, 1mM TCEP, and a 10-40mM gradient of Imidazole). After
washing, the loaded protein was eluted with an elution buffer (Same as wash buffer but with 300 mM Imidazole). The eluted protein
was dialyzed overnight against a storage buffer (20mMHEPES pH 8.0, 100 mM KCl, 5% glycerol, 40 mMPLP, 0.5 mM TCEP). TrpAB
were identified using SDS-PAGE gel, aliquoted, and stored at -80C until use. The concentration of the complex was measured
spectrophotometrically using the Pierce BCA Assay kit (ThermoFisher) and the accompanying BSA standards. The concentrationsCell Chemical Biology 28, 1–12.e1–e20, August 19, 2021 e5
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expression of TrpB in comparison to TrpA (~2:1 TrpB:TrpA), concentration of the TrpAB complex was adjusted to the percent
TrpA present, assuming any extra TrpB was inactive enzyme.
Preparation of Indole-3-glyceraldehyde phosphate (IGP)
To test the a-reaction of TrpAB, isolation and purification of the substrate indole-3-glycerol phosphate (IGP) was necessary. IGP is
not available commercially and no chemical synthesis method has been published, so we developed a method to enzymatically
synthesize IGP. We used E. coli indole-3-glycerol phosphate synthase (TrpCF) to convert 1-(o-carboxyphenylamino)-deoxyribulose
5-phosphate (CdRP) to IGP via an irreversible ring closure reaction spurred by decarboxylation and dehydration steps. The trpCF
gene was amplified from E. coliMG1655 genomic DNA using primers 1035 (F) and 1036 (R) and Q5 Hot-start high-fidelity 2X master
mix (New England Biolabs). The amplicon and pET28a was double digested with NdeI and HindIII; the vector was also treated with
alkaline phsphatase (CIP, New England Biolabs). The DNA digests were gel purified and ligated using T4 DNA ligase (New England
Biolabs) overnight at room temperature. The ligation mixture was transformed into competent E. coli NEB5a, the pET28a-(Ec)TrpCF
plasmid extracted and analyzed via Sanger sequencing (Eurofins). The plasmid carrying the correct sequence was transformed into
E. coliBL21(DE3) cells grown in the presence of 50 mg/mL kanamycin. An overnight culture of BL21 expressing TrpCFwas transferred
to 2 L of LB + 50 mg/mL kanamycin and allowed to grow to an OD600 of 0.6. Protein expression was induced by addition of IPTG to a
final concentration of 500 mM and incubation for an additional 3 hrs at 37C. The cells were harvested by centrifugation at 4000xg for
10 mins. The cells were resuspended in 30 mL of lysis buffer (50 mM Tris-HCl, pH 8.0; 500 mM NaCl, 5 mM imidazole, and 1X pro-
tease inhibitor cocktail (tablets from Roche)) and disrupted via sonication (cooling on ice for 1 min every 30 sec sonic bursts). The
lysate was centrifuged at 45000xg for 1 hour and the supernatant was loaded onto a Ni-NTA column equilibrated with 25 mL of col-
umn buffer (20 mM Tris-HCl, pH 8.0, 200 mM NaCl, 5 mM imidazole). The column was washed with 30 mL of column buffer with
increasing imidazole concentrations (5 mM, 10 mM, 20 mM, and 40 mM imidazole). The protein was eluted using 10 mL of column
buffer containing 300 mM imidazole and collected in 1 mL fractions. The fractions containing purified TrpCF (as seen from a
Coomassie-stained polyacrylamide gel) were pooled together and concentrated to ~2.5mL. The protein was buffer exchanged using
a PD-10 (Sigma-Aldrich) column equilibrated using 30 mL of storage buffer (20 mM Tris-HCl, and 5% glycerol) and eluted from the
PD-10 column using 3 mL of storage buffer. The protein were split into 300 mL aliquots and flash frozen using a dry ice/isopropanol
bath and stored at -80C until use. The protein concentration was measured spectrophotometrically using the Pierce BCA Assay kit
(ThermoFisher) and the accompanying BSA standards.
To generate CdRP, we followed chemical synthesis protocols previously reported (Czekster et al., 2009). After desiccation, CdRP
powder was protected from light and stored at -20C. In preparation for enzymatic conversion, 10mM CdRP was dissolved in 1.0 M
Tris-HCl, pH 7.5. To a reaction volume of 2 mL, the 10mMCdRPwas incubated with ~100ug of E. coli TrpCF overnight at 37C. After
incubation, to separate out the enzyme from IGP, the solution was loaded onto a 10,000MW filter and centrifuged. The resulting elute
was aliquoted and stored at -20C. Conversion of CdRP to IGP was confirmed via LC-MS. Because no CdRP could be detected via
LC-MS after overnight incubation, the concentration of resulting IGP was calculated by incubating IGP overnight with excess TrpAB
and quantifying the amount of L-Trp present with LC-MS-based L-Trp standard curve.
Kinetic characterization of recombinant Mtb TrpAB
The TrpAB kinetics was monitored with an absorbance-based assay using a ClarioStar multiwell plate reader. The activity of the
a-subunit was coupled to the activity of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 100 nM TrpAB was prepared in
the TrpAB storage buffer with 2.5mMNAD+, 30mMsodium arsenate, 1 mgGAPDH, and increasing amounts of either IGP or L-Serine.
The KM and kcat values for the a-reaction were calculated using the rates obtained from varying IGP concentrations. Because the
activity of the TrpAB subunits is tightly coupled, such that no TrpA product will be produced without the binding of L-Ser to TrpB,
we utilized as an analog, the formation of G3P from TrpA (under varying concentrations of L-Ser) to indirectly monitor the progress
of the b-reaction. Therefore, KM and kcat values for the b-reaction were calculated using the rates obtained from increasing
concentrations of L-Ser. The enzyme mix was aliquoted into the wells of clear, flat bottom 96-well plate. The reaction was initiated
with the addition of substrate and monitored by following the NADH absorbance at 340nm (εNADH = 6300 M
-1 cm-1).
To monitor the b-reaction exclusively (Indole + L-Ser/ L-Trp) a spectrophotometric monitoring was employed (Shen et al., 2009;
Xu andAbeles, 1993) using aClarioStarmultiwell plate reader. 50 nMof TrpABWTor 200 nMof TrpABmutants (themutants exhibited
significant attenuation in enzymatic activity that we could only reproducibly assay the kinetics at higher enzyme concentrations) were
prepared in TrpAB storage buffer containing 40 mMPLP and 20 mM L-Ser. To the enzyme mix was added increasing concentrations
of indole (stock solution prepared at 100mM inMeOH and diluted to the appropriate concentrations in the TrpAB storage buffer) and
the progress of reaction wasmonitored at 290 nm. The absorbance values were converted to rates using the difference in absorption
between indole and L-Trp at 290 nm (Dε = 1850 M-1 cm-1) (Xu and Abeles, 1993). All kinetic measurements were done at 25C.
Mtb TrpAB inhibition studies
Inhibition of the a-reaction was monitored by coupling the activity of the a-subunit to that of GAPDH. The mixtures (total volume
200 mL) were prepared in TrpAB storage buffer and included 100 nM TrpAB, 50 mM IGP, 20 mM L-Ser, 2.5 mMNAD+, 30 mM sodium
arsenate, 1 mgGAPDH, and increasing concentrations of inhibitors. The reactionwas initiated by addition of the enzyme and progress
was monitored by following the NADH absorbance at 340nm (εNADH = 6300 M
-1 cm-1). Inhibition of the b-reaction was monitored ate6 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
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100 nM TrpAB, 0.1 mM Indole, and 3 mM L-Ser (KM
L-Ser of TrpAB b-half reaction was calculated to be 2.9 ± 0.3 mM in a separate
determination, data not shown) in the presence of increasing inhibitor concentrations. The reaction was initiated by addition of
the enzyme and the progress was monitored by recording the absorbance at 290 nm. All inhibition studies were done at 25C.
Activity of Mtb TrpAB b-reaction using 4-AI as substrate
A LC-MS-based assay was developed to detect and quantify the conversion of 4-AI to 4-aTrp. 50 nM TrpAB WT and mutant TrpAB
were prepared in TrpAB buffer with 30 mM L-Serine. The reaction was initiated by the addition of increasing amounts of 4-amino-
indole. After 5 minutes of incubation, the reaction was quenched with an equal volume of 0.1% formic acid in methanol followed
by centrifugation. 2 mL of the collected supernatant was injected into the LC-MS. 4-aminotryptophan was separated and detected
on an Agilent 1100 HPLC system with a single quadrupole mass selective detector (G1946) using a Waters Acquity BEH Amide
2.1 mm by 50mm 1.7mm particle column. The mobile phase was aqueous with 0.1% formic acid (channel A) and Acetonitrile with
0.1% formic acid (channel B). Gradient of 95% B was initiated and linearly changed to 50% B over 10 minutes at flow rate
0.3mL/min. Compoundswere quantified by diode array detector with absorbance at 220nm. Tandem confirmationwas implemented
by scanning in positive mode with electrospray ionization (ESI+) for the M+H+ adduct at 220m/z. Response units obtained from the
LC-MS were converted to mM units using a separately determined calibration curve using synthetic 4-aTrp.
Further confirmation of 4-aTrp by TrpAB WT was determined on an Agilent 1290 infinity with triple quadrupole mass selective
detector (6460C). Confirmation was determined by retention time (same column / mobile phase) and energy resolved mass
spectrometry (erms) profile with CEV 0-70V (E = 0 to 7.9eV) for both enzymatic product and synthetic standard.
Intracellular metabolic incorporation of 4-AI into 4-aTrp
The 4-aTrp concentration following 4-AI treatment of Mtb was done exactly the same as the compound metabolism studies
described above, except that to quench the metabolism, the aliquots were transferred to an equal volume of 1:1 ACN:MeOHmixture
prior to filtering out the cells in the mixture. The 4-aTrp was detected and quantified using the LC-MS equipped with BEH amide


















All reagents including solvents used in the synthetic procedure were purchased from Sigma-Aldrich and used without further
purification unless otherwise mentioned. NMR was performed by either a Bruker AVANCE III HD NanoBay 400 MHz, Spectrometer
or Bruker Avance DPX 400, Bruker Avance DPX 500 spectrometer, and chemical shifts were measured in ppm relative to specific
solvent signal. Routine mass and purity analyses (LRMS) were performed on:
d HP Agilent LC/MS series 1100 system equipped with a reverse phase column (Agilent Poroshell 120 EC-C18, 2.7 mm, 50 X
2.1mm) and photodiode array detector coupled to an Agilent 1946 DSL quadrupole mass selective detector using electrospray
ionization (ESI).
d Bruker MicrOTOF II focus ESI Mass Spectrometer connected in parallel to Dionex Ultimate 3000 RSLC systemwith diode array
detector equipped with a reverse phase column (Waters XBridge C18 column, 2.1 x 50mm, 3.5 mm particle size) using ESI.
d HP Agilent LC/MS series 1100 system equipped with a reverse phase column (Kinetex EVO C18 column, 5 mm, 30 x 2.1 mm)
and photodiode array detector coupled to an Agilent G1956A quadrupole mass selective detector using electrospray
ionization (ESI)
d HP Agilent LC/MS series 1260 system equipped with a reverse phase column (Kinetex EVO C18 column, 5 mm, 30 x 2.1 mm)
and photodiode array detector coupled to an Agilent G6110A quadrupole mass selective detector using electrospray
ionization (ESI)Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021 e7
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array detector coupled to a Shimadzu LCMS-2020 mass selective detector using electrospray ionization (ESI)
d The compounds were eluted with a gradient of 5 to 95%MeCN/water +0.025 or 0.1%Ammonia, or +0.1% FA or 0.0375% TFA.
The purification of compounds was performed by flash column purification using SiliaFlash P60 (40–60 mm) or by preparative
HPLC using one of the following methods:
d Method A. Varian preparative HPLC system equipped with a reverse phase column (Phenomenex Luna C18, 10 mm, 250 x
21.2 mm) and photodiode array detector.
d Method B: Gilson preparative HPLC system equipped with a reverse phase column (Column: Phenomenex Synergi C18
150*25*10 mmum) and a photodiode array detector; Mmobile phase: [water (0.225% FA)-MeCN]; B%: 35%-65%, 10 min)
d Method C: Gilson preparative HPLC system equipped with a reverse phase column Column: PPhenomenex Synergi C18
150*30 mm*4 mmum) and a photodiode array detector; Mmobile phase: [water (0.225% FA)-MeCN]; B%: 45%-72%, 12 min)
d Method D: Gilson preparative HPLC system equipped with a reverse phase column Column: Phenomenex Synergi C18
150*25*10 mmum) and a photodiode array detector; Mobile phase: [water (0.225% FA)-MeCN]; B%: 20%-50%, 10 min)
d Method E: Gilson preparative HPLC system equipped with a reverse phase column Column: Phenomenex Gemini
150*25 mm*10 mmum) and a photodiode array detector; Mobile phase: [water (0.04% NH4OH+10mM NH4HCO3)-MeCN]; B
%: 35%-65%, 10 min
d Method F: Gilson preparative HPLC system equipped with a reverse phase column ( Phenomenex Synergi C18 150*25*10 mm)
and a photodiode array detector; Mobile phase: [water (0.225% FA)-MeCN]; B%: 50-80%, 10 min)
d Method G: Gilson preparative HPLC system equipped with a reverse phase column (Phenomenex column: Gemini
150*25 5mmu) and a photodiode array detector; mMobile phase: [water (0.05% ammonia hydroxide v/v)-MeCN]; B%:
46%-76%, 12 min
d MethodH: Gilson preparative HPLC systemequippedwith a reverse phase column: PhenomenexGemini 150*25mm*10mmum)
and a photodiode array detector; mMobile phase: [water (0.04%NH4OH+10mM NH4HCO3)-MeCN]; B%: 37%-67%, 9 min
d Method I: Gilson preparative HPLC system equipped with a reverse phase column Phenomenex Gemini 150*25mm*10ummm)
and a photodiode array detector; mobile phase: [water (0.04%NH4OH+10mM NH4HCO3)-MeCN]; B%: 40%-70%, 9.5 min
d Method J: Gilson preparative HPLC system equipped with a reverse phase column column: Phenomenex Synergi C18
150*25*10mmum) and a photodiode array detector; mobile phase: [water (0.225%FA)-MeCN]; B%: 40%-70%, 9min
d Method K: Enamine Instrument: Agilent 1260 Infinity HPLC systems equipped with a reverse phase column DAD andmass-de-
tector Column: (Waters Sunfire C18 OBD Prep Column, 100 A, 5 mm, 19 mm x 100mmwith SunFire C18 Prep Guard Cartridge,
100 A, 10 mm, 19 mm x 10 mm) Detection: DAD – DAD1A 215 nm, DAD1B 254 nm. MSD – single quadrupole, AP-ESI Mobile
phases: A - Deionized water (100%). B - HPLC-grade MeOH (100%) Gradient: from A-50%: B-50% to A-0%: B-100%.
d Method L: Gilson preparative HPLC system equipped with a reverse phase column column: Phenomenex Synergi C18
150*25*10mmum) and a photodiode array detector; Mmobile phase: [water (0.225%FA)-MeCN]; B%: 45%-75%, 9min
All reagents including solvents used in the synthetic procedure were purchased from Sigma-Aldrich and used without further
purification unless otherwise mentioned. Synthesized compounds were R95% pure (by LCMS and 1H NMR) unless otherwise
stated.
Synthesis of mixture, 4-nitro-L-tryptophan and 6-nitro-L-tryptophan (1)
To a suspension of L-tryptophan (0.2g, 0.97mmol) in 4mLAcOH and 1mLH2Owas dropwise added 70%HNO3 (0.2mL, 2.95mmol).
The reaction mixture was stirred at room T for about 4 h. After evaporation, it was purified by preparative HPLC system in the con-
dition of 20 mL/min of flow rate with linear gradient over 30 min (solvent A was 0.1% HCOOH in water and B was 0.1% HCOOH in
ACN, the detection wavelength was 330 nm). A yellow solid mixture of 4- and 6-nitro-L-tryptophan was obtained (50 mg, 20% yield):
1H NMR (400MHz, DMSO-d6) d 8.34 (d, J = 1.9 Hz, 1H), 7.977.93 (m, 1.5H), 7.797.76 (m, 1.5H), 7.56 (s, 1H), 7.50 (s, 0.5H), 7.26 (t,
J = 8.0 Hz, 0.5H), 4.114.03 (m, 1.5H), 3.74 (dd, J = 5.5 and 14.7 Hz, 0.5H), 3.49 (dd, J = 4.6 and 15.2 Hz, 1H), 3.373.30 (m, 1.5H);
LRMS (ESI) m/z 250 [M + H]+.
Synthesis of Boc protected 4-nitro-L-tryptophan (2)
To a solution of 1 (50 mg, 0.2 mmol) in 5 mL of MC were added Boc anhydride (0.13g, 0.6 mmol), DMAP (0.07g, 0.6 mmol), and NEt3
(0.11mL, 0.8mmol). The reactionmixture was stirred overnight at room. The reactionmixture was diluted with EtOH andwashedwith
0.1N HCl and brine. The organic layer was dried over Na2SO4 and evaporated in vacuo. The crude mixture was purified by flash col-
umn chromatography (EtOAc / hexane = 4 / 1 with 0.4% AcOH) to obtain the desired product 2 (20 mg, 22%): 1H NMR (400MHz,
CDCl3) d 8.56 (d, J = 7.6 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.72 (s, 1H), 7.36 (t, J = 7.9 Hz, 1H), 5.14 (d, J = 8.4 Hz, 1H), 4.59 (d, J =
4.4 Hz, 1H), 3.47 (dd, J = 3.2 and 15.1 Hz, 1H), 3.15 (dd, J = 9.3 and 14.7 Hz, 1H), 1.67 (s, 9H), 1.33 (s, 9H); LRMS (ESI) m/z 448
[M - H]-.
Synthesis of 4-amino-L-tryptophan (4)
To a solution of 1 (20 mg) in 3 mL MeOH was added 5 mg of 10 wt.% Pd/C. The reaction mixture was stirred for about 2 h at room
temperature under a H2 balloon. After filtration of the reaction mixture through a pad of celite, it was evaporated and used in the nexte8 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
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was stirred for about 2 h at roomT. After evaporation, it was purified by preparative HPLC system in the condition of 20mL/min of flow
rate with A / B = 95 / 5 over 10 min (solvent A was 0.1% HCOOH in water and B was 0.1%HCOOH in ACN, the detection wavelength
was 270 nm) to obtain desired product 4 as a TFA salt (13 mg, 87%): 1H NMR (400MHz, D2O) d 7.58 (d, J = 8.3 Hz, 1H), 7.43 (s, 1H),
7.25 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 7.4 Hz, 1H), 4.23 (t, J = 5.0 Hz, 1H), 3.57 (dd, J = 5.4 and 16.2 Hz, 1H), 3.46 (dd, J = 4.2 and 16.0 Hz,
1H); 13C NMR (100MHz, D2O) d 162.9, 162.5, 137.9, 127.3, 121.9, 121.8, 121.6, 119.4, 114.7, 113.2, 104.4, 25.8; LRMS (ESI) m/z 220
[M + H]+.
N-(1H-indol-4-yl)-2-phenoxyacetamide (C2)
To a solution of 1H-indol-4-amine (104 mg, 0.788mmol) and 2-phenoxyacetic acid (100 mg, 0.657 mmol in DMF (1 mL) was added
EDCI (189 mg, 0.985mmol), HOBt (133mg, 0.985 mmol) and DIPEA (0.343 mL,1.97 mmol) and the solution was stirred at 25C for 20
hours. The mixture was poured into an ice-water (5 mL), the resulting precipitate collected by filtration, washed with water (2 mL33)
and dried under vacuum. The crude product was purified by Prep-HPLC (Method B) to give the desired compound C2 (54.0 mg,
30.5% yield) as a dark solid. 1H NMR (400MHz, DMSO-d6) d 1.18 (br s, 1H), 9.76 (s, 1H), 7.54 (br d, J=7.5 Hz, 1H), 7.39 - 7.28 (m,
3H), 7.20 (br d, J=7.9 Hz, 1H), 7.08 - 6.95 (m, 4H), 6.60 (br s, 1H), 4.82 (s, 2H); LRMS (ESI) m/z 267.0 [M + H]+.
N-(1H-indol-4-yl)cyclohexanecarboxamide (C3)
To a solution of cyclohexanecarboxylic acid (100 mg, 0.78 mmol) and 1H-indol-4-amine (123 mg, 0.936 mmol) in DMF (2 mL) was
added HATU (593 mg, 1.56 mmol) and DIPEA (504 mg, 3.90 mmol) and the solution was stirred at 25C for 4 hours. The mixture was
poured into an ice-water (5 mL), the resulting precipitate collected by filtration, washed with water (2 mL33) and dried under vacuum.
The crude product was purified by Prep-HPLC (Method B) to give the desired compoundC3 (50.4mg, 96.4% yield) as a gray solid. 1H
NMR (400 MHz, DMSO-d6): d 11.07 (br s, 1H), 9.40 (s, 1H), 7.57 (d, J=7.6 Hz, 1H), 7.27 (t, J=2.8 Hz, 1H), 7.12 (d, J=8.2Hz, 1H), 7.04 –
6.95 (m, 1H), 6.70 (br s, 1H), 2.53 (br s, 1H), 1.86 – 1.75 (m, 4H), 1.67 (br d, J=11.4 Hz, 1H), 1.50 – 1.39 (m, 2H), 1.34 – 1.18 (m, 3H);
LRMS (ESI) m/z 243.1 [M + H]+
N-(1H-indol-4-yl)-5-(2,2,2-trifluoroethoxy)picolinamide (C4)
Step 1.
To a mixture of methyl 5-hydroxypicolinate (200 mg, 1.31 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (454 mg,
1.96mmol) inMeCN (5mL) was added cesium carbonate (638mg, 1.96mmol) at 0Cand themixturewas stirred at 25C for 10 hours.Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021 e9
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ammonium chloride solution (200 mL) and stirred for 5 min. The pH of the mixture was adjusted to pH=3 with HCl (aq,1M) and the
aqueous phase was extracted with EtOAc (30 mL33). The combined organic phases were washed with brine (20 mL), dried with
anhydrous anhydrous sodium sulfate, filtered and concentrated in vacuo to give methyl 5-(2,2,2-trifluoroethoxy)picolinate
(180 mg, 50.5% yield) as a white solid which was used without further purification. 1H NMR (400MHz, DMSO-d6) d= 8.56
(d, J=2.8 Hz, 1H), 8.14 (d, J=8.8 Hz, 1H), 7.73 (dd, J=3.2, 8.8 Hz, 1H), 5.05 (q, J=8.8 Hz, 2H), 3.91 (s, 3H); LRMS (ESI) m/z 236.1
[M + H]+
Step 2.
To a mixture of give methyl 5-(2,2,2-trifluoroethoxy)picolinate (180mg, 0.765 umol) in MeOH (6 mL) was added a solution of lithium
hydroxide monohydrate (96.4 mg, 2.30 mmol) in water (2 mL) at 25C and the mixture was stirred at 25C for 12 hours. The pH of the
mixture was adjusted to pH=5 with AcOH (0.15 mL), stirred for 20 min and extracted with EtOAc (30 mL33). The combined organic
phase was washed with brine (30 mL), dried with anhydrous anhydrous sodium sulfate, filtered and concentrated in vacuo to give
5-(2,2,2-trifluoroethoxy)picolinic acid (110 mg, 64.4% yield) as a white solid. LRMS (ESI) m/z 222.0 [M + H]+
Step 3.
To a mixture of 5-(2,2,2-trifluoroethoxy)picolinic acid (100 mg, 0.452 mmol) and 1H-indol-4-amine (59.8 mg, 0.452 mmol) in DMF
(5 mL) was added HATU (343 mg, 0.904 mmol) and DIPEA (292.23 mg, 2.26 mmol) in one portion at 25C and the mixture was stirred
for 10 hours. The mixture was filtered and the filtrate was concentrated in vacuo to give a crude residue which was purified by prep-
HPLC (MethodC) to give the desired compoundC4 (59.5mg, 39.0%yield) as awhite solid. 1HNMR (400MHz, DMSO-d6) d = 11.28 (br
s, 1H), 10.26 (s, 1H), 8.58 (d, J=2.8 Hz, 1H), 8.21 (d, J=8.7 Hz, 1H), 7.83 - 7.76 (m, 2H), 7.39 (t, J=2.8 Hz, 1H), 7.24 (d, J=8.1 Hz, 1H),
7.11 (t, J=7.9 Hz, 1H), 6.52 (br s, 1H), 5.04 (q, J=8.8 Hz, 2H); LRMS (ESI) m/z 336.1 [M + H]+
N-(1H-indol-5-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (C6)
To a solution of 1H-indol-5-amine (35.8 mg, 0.271 mmol) and 6-(2,2,2-trifluoroethoxy)nicotinic acid (50 mg, 0.226 mmol, 1 eq) in
DMF (0.5 mL) was added EDCI (65.0 mg, 0.339 mmol), HOBt (45.8 mg, 0.339mmol) and DIPEA (87.6 mg, 0.678mmol and the solution
was stirred at 25C for 20 hours. The mixture was poured into an ice-water (5 mL), the resulting precipitate collected by filtration,
washed with water (2 mL33) and dried under vacuum. The crude product was purified by Prep-HPLC (Method D) to give the desired
compoundC6 (20.47 mg, 27.0% yield) was obtained as a white solid. 1H NMR (400 MHz, DMSO-d6): d 11.06 (br s, 1H), 10.17 (s, 1H),
8.82 (d, J=2.2 Hz, 1H), 8.35 (dd, J=2.4, 8.6 Hz, 1H), 7.97 (s, 1H), 7.40 - 7.30 (m, 3H), 7.14 (d, J=8.7 Hz, 1H), 6.45 - 6.39 (m, 1H), 5.11 (q,
J=9.0 Hz, 2H); LRMS (ESI) m/z 336.0 [M + H]+.e10 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
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drug metabolism and tryptophan biosynthesis, Cell Chemical Biology (2021), https://doi.org/10.1016/j.chembiol.2021.02.023N-(1H-indol-6-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (C7)
Using a similar method to C6, except using 1H-indol-6-amine (35.8 mg, 0.271 mmol) the desired compound C7 (18.8 mg, 24.8%
yield) was obtained as a white solid. 1H NMR (400 MHz, DMSO-d6): d 11.08 (br s, 1H), 10.25 (s, 1H), 8.81 (d, J=2.1 Hz, 1H), 8.35 (dd,
J=2.4, 8.6 Hz, 1H), 8.05 (s, 1H), 7.49 (d, J=8.6 Hz, 1H), 7.34 - 7.22 (m, 2H), 7.14 (d, J=8.6 Hz, 1H), 6.39 (br s, 1H), 5.11 (q, J=9.0 Hz, 2H);
LRMS (ESI) m/z 336.0 [M + H]+.
N-(1H-indol-7-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (C8)
Using a similar method to C6, except using 1H-indol-7-amine (35.8 mg, 0.271 mmol), the desired compound C8 (39.1 mg, 51.6%
yield) was obtained as a white solid. 1H NMR (400 MHz, DMSO-d6): d 10.92 (br s, 1H), 10.22 (s, 1H), 8.90 (d, J=2.2 Hz, 1H), 8.41 (dd,
J=2.4, 8.7 Hz, 1H), 7.50 - 7.27 (m, 3H), 7.17 (d, J=8.7 Hz, 1H), 7.01 (t, J=7.7 Hz, 1H), 6.48 (dd, J=2.0, 2.9 Hz, 1H), 5.13 (q, J=9.0 Hz, 2H);
LRMS (ESI) m/z 336.0 [M + H]+.
N-(1-methyl-1H-indol-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (C9)
Using a similar method to C6, except using 1-methylindol-4-amine (39.6 mg, 0.271 mmol), the desired compound C9 (30.2 mg,
38.1% yield) was obtained as a white solid. 1H NMR (400 MHz, DMSO-d6): d 10.20 (s, 1H), 8.85 (d, J=2.1 Hz, 1H), 8.37 (dd,
J=2.3, 8.7 Hz, 1H), 7.49 - 7.09 (m, 5H), 6.61 (d, J=2.9 Hz, 1H), 5.12 (q, J=9.0 Hz, 2H), 3.81 (s, 3H); LRMS (ESI) m/z 350.0 [M + H]+.
N-((6-(2,2,2-trifluoroethoxy)pyridin-3-yl)methyl)-1H-indol-4-amine (C10)
Step 1.Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021 e11
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drug metabolism and tryptophan biosynthesis, Cell Chemical Biology (2021), https://doi.org/10.1016/j.chembiol.2021.02.023To a solution of 6-(2,2,2-trifluoroethoxy)pyridine-3-carboxylic acid (100 mg, 0.452 mmol and N-(1H-indol-4-yl)-6-(2,2,2-tri-
fluoroethoxy)nicotinamide (71.7 mg, 0.542 mmol) in DMF (1 mL) was added EDCI (130 mg, 0.678 mmol), HOBt (91.6 mg,
0.678 mmol) and DIPEA (175 mg, 1.36 mmol) and the solution was stirred at 25C for 16 hours. The mixture was poured
into an ice-water (5 mL), the resulting precipitate collected by filtration, washed with water (2 mL33) and dried under vacuum
to give N-(1H-indol-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (120 mg, 79.2%) as a black solid. LRMS (ESI) m/z 336.0
[M + H]+
Step 2.
To a solution of N-(1H-indol-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (100 mg, 0.298 mol) in THF (1 mL) was added
BH3dTHF (1 M, 0.596 mL) at 25
C and the solution was stirred at 50C for 3 hours. The reaction mixture was concentrated
in vacuo to give a crude residue which was azetroped with EtOAc (2 mL33). The crude product was purified by Prep-
HPLC (Method F). to give the desired compound C10 (27.3 mg, 27.6% yield) as a gray solid. 1H NMR (400 MHz, DMSO-
d6) d 10.82 (br s, 1H), 8.21 (d, J=2.0 Hz, 1H), 7.80 (dd, J=2.4, 8.5 Hz, 1H), 7.12 - 7.08 (m, 1H), 6.95 - 6.86 (m, 1H), 6.83 -
6.74 (m, 1H), 6.69 - 6.58 (m, 2H), 6.23 (t, J=6.2 Hz, 1H), 6.00 (d, J=7.6 Hz, 1H), 4.95 (q, J=9.2 Hz, 2H), 4.38 (d, J=6.2 Hz,
2H), 1.11 - 0.99 (m, 1H); LRMS (ESI) m/z 322.1 [M + H]+
N-(6-(2,2,2-trifluoroethoxy)pyridine-3-yl)-1H-indole-4-carboxamide (C11)
Step 1.
To a mixture of sodium hydride (45.4 mg, 1.14 mmol, 60% w/w) in DMF (10 mL) was added 2,2,2-trifluoroethanol (100 mg,
999 umol, 1.06 eq) at 0C and the mixture was stirred at 0C for 1 hour. A solution of 2-chloro-5-nitropyridine (150 mg,
0.946 mmol) in DMF (10 mL) was added to the cooled reaction mixture at 0C and the mixture was stirred at 25C for 2 hours.
The reaction was concentrated in vacuum to remove most of the solvent. The residue was poured into saturated of ammonium
chloride solution (200 mL) and stirred for 5 min. The aqueous phase was extracted with EtOAc (30 mL33). The combined
organic phases were washed with brine (20 mL), dried with anhydrous anhydrous sodium sulfate, filtered and concentrated
in vacuo to give 5-nitro-2-(2,2,2-trifluoroethoxy)pyridine (120 mg, 54.1% yield) as a white solid. 1H NMR (400MHz, DMSO-
d6): d 9.12 (d, J=2.8 Hz, 1H), 8.59 (dd, J=2.8, 9.2 Hz, 1H), 7.25 (d, J=9.2 Hz, 1H), 5.16 (q, J=9.2 Hz, 2H); LRMS (ESI) m/z
223.0 [M + H]+
Step 2.
To a solution of 5-nitro-2-(2,2,2-trifluoroethoxy)pyridine (120 mg, 0.540 mmol) in MeOH (10 mL) was added 10% Pd/C (40 mg) un-
der H2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at
20C for 4 hours. The reaction was filtered and the filtrate concentrated in vacuo to give 6-(2,2,2-trifluoroethoxy)pyridin-3-amine
(100 mg, 96.3% yield) as a yellow oil. 1H NMR (400MHz, DMSO-d6): d 7.51 (d, J=2.8 Hz, 1H), 7.07 (dd, J=2.8, 8.8 Hz, 1H), 6.69
(d, J=8.8 Hz, 1H), 4.93 (s, 2H), 4.80 (q, J=9.2 Hz, 2H)e12 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
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To a mixture of 6-(2,2,2-trifluoroethoxy)pyridin-3-amine (100 mg, 0.520 mmol) and 1H-indole-4-carboxylic acid (83.8 mg,
0.520mmol) in pyridine (10mL) was added EDCI (299mg, 1.56mmol) in one portion at 25C, the reaction warmed to 45C and stirred
for 10 hours. The reaction was concentrated in vacuo to remove most of the solvent, the residue was poured into water (20 mL) and
stirred for 5 minutes. The aqueous phase was extracted with EtOAc (30 mL33), the combined organic phases were washed with
brine (20 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by prep-HPLC
(Method B) to give the desired compound C11 (74.2 mg, 42.5% yield) as a white solid. 1H NMR (400MHz, DMSO-d6): d 11.41 (br
s, 1H), 10.31 (s, 1H), 8.62 (d, J=2.5 Hz, 1H), 8.21 (dd, J=2.6, 8.9 Hz, 1H), 7.64 (d, J=8.0 Hz, 1H), 7.59 (d, J=7.2 Hz, 1H), 7.50 (t,





To a solution of 6-(2,2,2-trifluoroethoxy)nicotinic acid (100 mg, 0.452 mmol) and 1H-indol-4-amine (71.7 mg, 0.542 mmol) in DMF
(1 mL) was added EDCI (130 mg, 0.678 mmol), HOBt (91.6 mg, 0.678 mmol) and DIPEA (175 mg, 1.36 mmol and the solution was
stirred at 25C for 20 hours. The mixture was poured into an ice-water (5 mL), the resulting precipitate collected by filtration, washed
with water (2 mL33) and dried under vacuum to give N-(1H-indol-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (140 mg, 87.90% yield)
was obtained as a black solid. LRMS (ESI) m/z 336.0 [M + H]+
Step 2.
N-(1H-indol-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (140 mg, 0.417 mmol) in AcOH (1 mL) was added sodium cyanoborohy-
dride (52.4 mg, 0.835 mmol) and the reaction was stirred at 25C for 4 hours. The mixture was poured into water (1 mL) and extracted
with EtOAc (15mL34). The combined organic layerswere dried over anhydrous sodium sulfate and concentrated in vacuo. The crude
product was purified by Prep-HPLC (Method D) to give N-(1-formylindolin-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (120 mg,
0.328 mmol). (ESI) m/z 366.0 [M + H]+Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021 e13
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To a solution of N-(1-formylindolin-4-yl)-6-(2,2,2-trifluoroethoxy)nicotinamide (120 mg, 0.328 mmol in water (0.5 mL) and EtOH
(0.5 mL) was added aq.HCl (4N, 1 mL) and the mixture was stirred for 6 hrs at 80C. The mixture was cooled to room temperature,
poured into an ice-water (5 mL), the resulting precipitate collected by filtration, washed with water (2 mL33) and dried under vacuum.
The crude product was purified by Prep-HPLC (Method E) to give the desired compound C12 (21.7 mg, 19.5% yield) as an orange
solid. 1H NMR (400 MHz, DMSO-d6): d 9.93 (s, 1H), 8.78 (d, J=2.1 Hz, 1H), 8.30 (dd, J=2.4, 8.6 Hz, 1H), 7.13 (d, J=8.6 Hz, 1H), 6.91 (t,
J=7.8 Hz, 1H), 6.64 (d, J=7.8 Hz, 1H), 6.38 (d, J=7.6 Hz, 1H), 5.56 (s, 1H), 5.10 (q, J=9.0 Hz, 2H), 3.46 - 3.39 (m, 2H), 2.88 (t, J=8.5 Hz,
2H); LRMS (ESI) m/z 338.0 [M + H]+.
N-(1H-indol-4-yl)-N-methyl-6-(2,2,2-trifluoroethoxy)nicotinamide (C13)
Step 1.
To amixture of 1H-indol-4-amine (200mg, 1.51mmol) in DMF (10mL) was added sodium hydride (72.63mg, 1.82mmol, 60%w/w)
in one portion at 0C and the mixture was stirred at 0C for 1 hour. Methyl iodide (257.75 mg, 1.82 mmol) was added into the mixture
whichwas stirred at 0C for 1 hour. The reaction was concentrated in vacuo to removemost of the solvent to give a residuewhichwas
poured into water (20 mL) and stirred for 5 min. The aqueous phase was extracted with EtOAc (30 mL*3). The combined organic
phases were washed with brine (20 mL), dried with anhydrous anhydrous sodium sulfate, filtered and concentrated in vacuo to
give N-methyl-1H-indol-4-amine (106 mg, 47.9% yield) as a white solid. LRMS (ESI) m/z 147.1 [M + H]+.
Step 2.
To a mixture of compound 6-(2,2,2-trifluoroethoxy)nicotinic acid (100 mg, 0.452 mmol) and N-methyl-1H-indol-4-amine (66.1 mg,
0.452 mmol) in pyridine (5 mL) was added EDCI (260 mg, 1.36 mmol) in one portion at 25C, the mixture was warmed to 45C and
stirred for 10 hours. The reaction was concentrated in vacuo to remove most of the solvent to give a crude residue which was poured
into water (20mL) and stirred for 5min. The aqueous phase was extracted with EtOAc (30mL*3). The combined organic phases were
washed with brine (20 mL), dried with anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by
prep-HPLC (Method F) to give the desired compound C13 (57.8 mg, 36.6% yield) as white solid. 1H NMR (400MHz, DMSO-d6):
d 10.22 (s, 1H), 8.85 (d, J=2.0 Hz, 1H), 8.37 (dd, J=2.4, 8.8 Hz, 1H), 7.43 (d, J=7.6 Hz, 1H), 7.33 - 7.28 (m, 2H), 7.19 - 7.11 (m, 2H),
6.61 (s, 1H), 5.12 (q, J=9.2 Hz, 2H), 3.81 (s, 3H); LRMS (ESI) m/z 350.1 [M + H]+.e14 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
ll
OPEN ACCESSArticle
Please cite this article in press as: Libardo et al., Resistance of Mycobacterium tuberculosis to indole 4-carboxamides occurs through alterations in
drug metabolism and tryptophan biosynthesis, Cell Chemical Biology (2021), https://doi.org/10.1016/j.chembiol.2021.02.023N-(1H-benzo[d]imidazol-4-yl)-5-(2,2,2-trifluoroethoxy)picolinamide (C14)
To a solution of 5-(2,2,2-trifluoroethoxy)picolinic acid (166mg, 0.751mmol) and 1H-benzimidazol-4-amine (100mg, 0.751mmol) in
DMF (2 mL) was added HATU (571 mg, 1.50 mmol) and DIPEA (485.32 mg, 3.76 mmol) and the solution was stirred at 40C for 16
hours. The mixture was poured into an ice-water (5 mL), the resulting precipitate collected by filtration, washed with water (2 mL33)
and dried under vacuum. The crude product was purified by Prep-HPLC (Method H) to give the desired product C14 (18.2 mg, 7.1%
yield) as a grey solid. 1H NMR (400 MHz, DMSO-d6) d 10.85 (s, 1H), 8.61 (br d, J=2.4 Hz, 1H), 8.28 - 8.18 (m, 3H), 7.82 (dd, J=2.8,
8.7 Hz, 1H), 7.32 - 7.19 (m, 2H), 5.05 (q, J=8.6 Hz, 2H); LRMS (ESI) m/z 337.1 [M + H]+.
N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-5-(2,2,2-trifluoroethoxy)picolinamide (C15)
Step 1.
To the solution of 5-(2,2,2-trifluoroethoxy)picolinic acid (400 mg, 1.81 mmol) and ammonium chloride (194 mg, 3.62 mmol) in DMF
(4mL) was added EDCI (520mg, 2.71mmol), HOBt (366.63 /mg, 2.71mmol) and DIPEA (701mg, 5.43mmol) and the reactionmixture
was stirred at 25C for 12 hours. The reaction was quenched with water (4 mL) and extracted with EtOAc (8 mL*3). The combined
organic layers were dried over anhydrous sodium sulfate and concentrated in vacuo to give 5-(2,2,2-trifluoroethoxy)picolinamide
(300 mg, 75.3% yield) as pink solid. 1H NMR (400 MHz, DMSO-d6) d 8.42 (d, J=2.8 Hz, 1H), 8.04 (d, J=8.8 Hz, 2H), 7.68 (dd,
J=2.9, 8.7 Hz, 1H), 7.54 (br s, 1H), 4.98 (q, J=8.8 Hz, 2H); LRMS (ESI) m/z 221.0 [M + H]+.
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drug metabolism and tryptophan biosynthesis, Cell Chemical Biology (2021), https://doi.org/10.1016/j.chembiol.2021.02.023To the solution of 1H-pyrrolo[2,3-b]pyridin-4-ylboronic acid (147 mg, 0.908 mmol) and 5-(2,2,2-trifluoroethoxy)picolinamide
(100 mg, 0.454 mmol) in DCM (2 mL) was added copper (II) acetate (165 mg, 0.908 mmol) and pyridine (108 mg, 1.36 mmol) and
the reaction mixture was stirred at 25C for 12 hours. The reaction mixture was concentrated in vacuo to give a crude residue which
was purified by Prep-HPLC (Method I) to give the desired product C15 (1.6 mg, 0.97% yield as yellow solid. 1H NMR (400 MHz,
DMSO-d6) d 11.73 (br s, 1H), 10.47 (s, 1H), 8.59 (d, J=2.9 Hz, 1H), 8.26 - 8.19 (m, 2H), 7.88 (d, J=5.3Hz, 1H), 7.82 (dd, J=2.8,
8.8 Hz, 1H), 7.49 - 7.44 (m, 1H), 6.63 (d, J=1.3 Hz, 1H), 5.09 - 5.03 (m, 2H); LRMS (ESI) m/z 337.1 [M + H]+.
N-(1H-indol-4-yl)-6-(2,2,2-trifluoroethoxy)pyridazine-3-carboxamide (C16)
Step 1.
To a suspension of sodium hydride (174 mg, 4.35 mmol, 60% w/w) in DMF (1 mL) was added 2,2,2-trifluoroethanol (348 mg,
3.48 mmol) dropwise at 0C and the mixture was stirred at 0C for 30 minutes. Methyl 6-chloropyridazine-3-carboxylate (500 mg,
2.90 mmol) in DMF (1 mL) was added dropwise at 0C and the mixture was stirred at 50C for 2.5 hours. The mixture was poured
into an ice-water (1 mL) and extracted with EtOAc (1 mL*3). The combined organic layer was washed with brine (1 mL*3), dried
over anhydrous sodium sulfate, filtered and the filtrate was concentrated in vacuo to give 6-(2,2,2-trifluoroethoxy)pyridazine-3-car-
boxylic acid (390 mg, 60.6% yield) as a yellow solid. LRMS (ESI) m/z 223.0 [M + H]+.
Step 2.
To a solution of 6-(2,2,2-trifluoroethoxy)pyridazine-3-carboxylic acid (390 mg, 1.76 mmol) and 1H-indol-4-amine (278 mg,
2.11 mmol) in DMF (2 mL) was added HATU (1.34 g, 3.51 mmol) and DIPEA (1.13 g, 8.78 mmol) and the solution was stirred at
25C for 4 hours. The mixture was poured into an ice-water (5 mL), the resulting precipitate collected by filtration, washed with water
(2 mL33) and dried under vacuum. The crude product was purified by Prep-HPLC (Method J) to give the desired product C16
(24.1 mg, 4.1% yield) as a grey solid. 1H NMR (400 MHz, DMSO-d6) d 11.26 (br s, 1H), 10.49 (s, 1H), 8.34 (d, J=9.0 Hz, 1H), 7.70
- 7.62 (m, 2H), 7.38 (t, J=2.8 Hz, 1H), 7.28 (d, J=8.2 Hz, 1H), 7.16 - 7.09 (m, 1H), 6.54 (br s, 1H), 5.34 (q, J=8.9 Hz, 2H); LRMS
(ESI) m/z 337.0 [M + H]+.
N-(1H-indol-4-yl)-2-(p-tolyloxy)acetamide (C17)
To a stirred solution of 2-(p-tolyloxy)acetic acid (0.183g, 1.1 mmol) and HOBt (0.203g, 1.5 mmol) in DMSO (2 mL) was added 4-
aminoindole (0.132g, 1 mmol) and the reaction stirred for 30 minutes. EDCI (0.186g, 1.2 mmol) was added and stirring continued
for 24 hours. The crude reaction mixture was purified by preparative HPLC (Method K), to give the desired product (C17) (0.103g,
36.8%) as an off-white solid. 1H NMR (400 MHz, DMSO) d 11.13 (s, 1H), 9.65 (s, 1H), 7.53 (d, J=7.6 Hz, 1H), 7.31 (dd, J=2.8,
2.8 Hz, 1H), 7.16 (dd, J=8.2, 26.6 Hz, 3H), 7.03 (dd, J=7.9, 7.9 Hz, 1H), 6.94 (d, J=8.5 Hz, 2H), 6.59 (s, 1H), 4.76 (s, 2H), 2.25 (s,
3H); HRMS (ESI) m/z 281.1308 [M + H]+.e16 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
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Using a similar method to C17, except using 2-(cyclopropylmethoxy)acetic acid (0.143g, 1.1 mmol), the desired compound (C18)
(0.089g, 36.5%) was obtained as an off-white solid. 1H NMR (400 MHz, DMSO) d 10.90 (s, 1H), 9.00 (s, 1H), 7.34 (d, J=7.7 Hz, 1H),
7.08 (dd, J=2.8, 2.8 Hz, 1H), 6.94 (d, J=8.2 Hz, 1H), 6.79 (dd, J=7.9, 7.9 Hz, 1H), 6.28 (s, 1H), 3.90 (s, 2H), 3.19 (d, J=6.9 Hz, 2H), 0.93 -
0.84 (m, 1H), 0.31 - 0.25 (m, 2H), 0.03 - 0.00 (m, 2H); HRMS (ESI) m/z 245.1300 [M + H]+.
(1s,3s)-N-(1H-indol-4-yl)-3-phenoxycyclobutane-1-carboxamide (C19)
Step 1.
To a solution of (1r,3r)-3-hydroxycyclobutane-1-carboxylic acid (300mg, 2.58mmol) and 1H-indol-4-amine (410mg, 3.10mmol) in
DMF (3 mL) was added HATU (1.96 g, 5.17 mmol) and DIPEA (1.67 g, 12.92 mmol) and the mixture was stirred at 40C for 16 hours.
The reaction was quenched with water (6 mL) and extracted with EtOAc (12 mL*3). The combined organic layers were dried over
anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by Reverse phase flash column (water/
MeCN+ 0.1% FA) to give (1r,3r)-3-hydroxy-N-(1H-indol-4-yl)cyclobutane-1-carboxamide (400 mg, 67.4% yield) as a pink solid. 1H
NMR (400 MHz, DMSO-d6) d 11.18 - 11.00 (m, 1H), 9.43 (s, 1H), 7.61 (d, J=7.6 Hz, 1H), 7.35 - 7.24 (m, 1H), 7.17 - 7.10 (m, 1H),
7.04 - 6.97 (m, 1H), 6.68 (br s, 1H), 5.16 (d, J=7.1 Hz, 1H), 4.11 - 3.92 (m, 1H), 2.89 - 2.75 (m, 1H), 2.44 - 2.30 (m, 2H), 2.44 - 2.30
(m, 1H), 2.14 - 1.98 (m, 2H); LRMS (ESI) m/z 231.1 [M + H]+.
Step 2.
To a solution of (1r,3r)-3-hydroxy-N-(1H-indol-4-yl)cyclobutane-1-carboxamide (400 mg, 1.34 mmol) in DCM (4 mL) was added
triethylamine (271 mg, 2.68 mmol) and methanesulfonyl chloride (307 mg, 2.68 mmol) and the mixture was stirred at 25C for
12 hrs. The reaction was quenched with water (1 mL) and extracted with EtOAc (2 mL*3). The combined organic layers were dried
over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was purified by Reverse phase flash column (water/
MeCN+ 0.1% FA) to give (1r,3r)-3-((1H-indol-4-yl)carbamoyl)cyclobutyl methanesulfonate (250 mg, 60.5% yield) as gray solid. 1H
NMR (400 MHz, DMSO-d6) d 11.10 (br s, 1H), 9.63 (br s, 1H), 7.58 (br d, J=7.5 Hz, 1H), 7.28 (br s, 1H), 7.16 (br d, J= 8.4 Hz, 1H),
7.07 - 6.95 (m, 1H), 6.66 (br s, 1H), 4.99 (br s, 1H), 3.22 - 3.05 (m, 3H), 2.67 (br s, 1H), 2.34 (br s, 4H); LRMS (ESI) m/z 309.0 [M + H]+.Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021 e17
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To a solution of phenol (114 mg, 1.22 mmol) in DMF (1.25 mL) was added cesium carbonate (528 mg, 1.62 mmol) and the mixture
was stirred at 80C for 1 hour. (1r,3r)-3-((1H-indol-4-yl)carbamoyl)cyclobutyl methanesulfonate (250 mg, 0.811 mmol) in DMF
(1.25 mL) was then added and the reaction mixture stirred at 80C for 1 hour. The reaction was quenched with water (2 mL) and
extracted with EtOAc (3 mL*3). The combined organic layers were dried over anhydrous sodium sulfate and concentrated in vacuo.
The crude product was purified by Prep-HPLC (Method L) to give the desired product C19 (4.2 mg, 1.7% yield) as a white solid. 1H
NMR (400MHz, DMSO-d6) d 7.65 (d, J = 7.6 Hz, 1H), 7.33 - 7.26 (m, 3H), 7.14 (d, J = 8.1 Hz, 1H), 7.05 - 6.98 (m, 1H), 6.93 (t, J = 7.3 Hz,
1H), 6.84 (br d, J = 8.2 Hz, 2H), 6.70 (br s, 1H), 4.90 (br t, J = 6.2 Hz, 1H), 3.51 (td, J = 4.8, 9.4 Hz, 1H), 2.74 - 2.67 (m, 2H), 2.39 - 2.32
(m, 2H); LRMS (ESI) m/z 307.1 [M+H]+.
N-(1H-indol-4-yl)-6-(methyl(2,2,2-trifluoroethyl)amino)nicotinamide (C20)
Step 1.
To the reaction mixture of methyl 6-bromonicotinate (600 mg, 3.50 mmol), 2,2,2-trifluoroethan-1-amine (520 mg, 5.25 mmol) and
t-BuONa (2M in THF, 5.25mL, 3 eq) in dioxane (6mL) was added tBuXPhos-Pd-G3 (277.78mg, 349.69 umol, 0.1 eq) under N2 and the
reaction was stirred at 90C for 12 hrs. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was
purified by column chromatography (SiO2, PetroleumEther: EtOAc = 10:1 -5:1) to givemethyl 6-((2,2,2-trifluoroethyl)amino)nicotinate
(230 mg, 27.7% yield) as light yellow solid. 1H NMR (400MHz, CDCl3) d 8.79 (d, J = 1.8 Hz, 1H), 8.05 (dd, J = 2.3, 8.7 Hz, 1H), 6.50
(d, J = 8.8 Hz, 1H), 5.03 (br s, 1H), 4.20 (dq, J = 6.8, 9.0 Hz, 2H), 3.89 (s, 3H); LRMS (ESI) m/z 235.1 [M+H]+.
Step 2.
Methyl 6-((2,2,2-trifluoroethyl)amino)nicotinate (230 mg, 0.982 mmol), methyl iodide (558 mg, 3.93 mmol) and cesium carbonate
(640 mg, 1.96 mmol) in DMF (2.5 mL) was stirred at 50C for 3 hrs. The reaction mixture was poured into saturated ammonium
chloride (5 mL) and extracted with EtOAc (2 mL*3). The combined organic layer was washed with brine (5mL), dried over anhydrous
sodium sulfate, filtered and the filtrate was concentrated in vacuo to give methyl 6-(methyl(2,2,2-trifluoroethyl)amino)nicotinate
(220 mg, 86.5% yield) as a grey solid. 1H NMR (400MHz, CDCl3) d 8.82 (d, J = 2.2 Hz, 1H), 8.11 (dd, J = 2.3, 8.9 Hz, 1H), 6.60
(d, J = 8.9 Hz, 1H), 4.42 (q, J = 9.0 Hz, 2H), 3.89 (s, 3H), 3.20 (s, 3H)); LRMS (ESI) m/z 249.1 [M+H]+.e18 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
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6-(methyl(2,2,2-trifluoroethyl)amino)nicotinate (120 mg, 0.483 mmol) and lithium hydroxide monohydrate (40.6 mg, 0.967 mmol) in
THF (0.6 mL) and water (0.6 mL) was stirred at 25C for 12 hrs. The reaction mixture was adjusted to pH=2 with aq.HCl (4M) and
extracted with EtOAc (2 mL*3). The combined organic layer was washed with brine (5 mL), dried over anhydrous sodium sulfate,
filtered and the filtrate was concentrated to give 6-(methyl(2,2,2-trifluoroethyl)amino)nicotinic acid (100mg, 88% yield) as a grey solid.
LRMS (ESI) m/z 235.1 [M+H]+.
Step 4.
6-(methyl(2,2,2-trifluoroethyl)amino)nicotinic acid (100 mg, 427.03 umol, 1 eq), 1H-indol-4-amine (56.4 mg, 0.427 mmol), HATU
(244mg, 641 umol) and DIPEA (166 mg, 1.28 mmol) in DMF (1.5 mL) was stirred at 25C for 12 hrs. The reaction mixture was concen-
trated in vacuo to give a crude residue which was purified by Prep-HPLC (Method L) to obtain the desired compound C20 (48.8 mg,
32.8% yield) as a grey solid. 1H NMR (400MHz, DMSO) d 11.10 (br s, 1H), 9.90 (s, 1H), 8.79 (d, J = 2.2 Hz, 1H), 8.19 (dd, J = 2.4, 8.9 Hz,
1H), 7.36 (d, J = 7.6 Hz, 1H), 7.29 (t, J = 2.8 Hz, 1H), 7.22 (d, J = 8.1 Hz, 1H), 7.09 - 7.03 (m, 1H), 6.91 (d, J = 8.9 Hz, 1H), 6.59 (d, J =
2.0 Hz, 1H), 4.59 (q, J = 9.6 Hz, 2H), 3.17 (s, 3H). LRMS (ESI) m/z 349.1 [M+H]+
N-(1H-indol-4-yl)-5-methylfuran-2-carboxamide (21)
1H-indol-4-amine (100mg, 0.757mmol), 5-methylfuran-2-carboxylic acid (86.8mg, 0.688mmol), HOBt (139mg, 1.03mmol), EDCI
(198 mg, 1.03 mmol) and DIPEA (267 mg, 2.06 mmol) in DMF (1 mL) was stirred at 25C for 12 hours. The reaction mixture was
concentrated in vacuo to give a crude residue which was purified by Prep-HPLC (Method L) to give the desired compound C21
(41.4 mg, 0.172 mmol, 25.0% yield) as a grey solid. 1H NMR (400MHz, DMSO) d 11.14 (br s, 1H), 9.74 (s, 1H), 7.33 - 7.23 (m, 4H),
7.11 - 7.03 (m, 1H), 6.53 (br s, 1H), 6.32 (d, J=2.7 Hz, 1H), 2.39 (s, 3H); LRMS (ESI) m/z 241.1 [M+H]+.Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021 e19
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Statistical analysis was performed in GraphPad Prism version 8.0.1 for Widnows, GraphPad Software, San Diego, Califonia
USA, www.graphpad.com. The number of biological replicates and statistical tests applied for each experiment is given in the
corresponding figure legend.e20 Cell Chemical Biology 28, 1–12.e1–e20, August 19, 2021
